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 The main body of this thesis in Chapter 3 is a journal article entitled 
“Development and Evaluation of Chitosan Paste as a Local Antibiotic Delivery System 
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Complex musculoskeletal wounds, resultant of high-energy trauma, are a leading 
cause of morbidity worldwide due, in part, to a propensity for bacterial contamination.  
This work details the fabrication of a thermo-responsive, injectable chitosan composite 
paste by including the additive β-glycerophosphate, which creates a polyelectrolyte 
complex with the chitosan molecular backbone.  Functional and clinical efficacy as an 
infection prevention tool were determined within the scope of complex musculoskeletal 
wounds.  Findings from in vitro studies support the capability of chitosan paste to be 
loaded with dual antibiotics for release of inhibitory levels of both amikacin and 
vancomycin for at least 3 days. Further, rates of enzymatic degradation of approximately 
60% of the initial mass were observed within 7 days.  The cytocompatibility of the 
thermogel requires enhancement; eliciting the lowest cell count among all experimental 
groups, approximately 77% of the Control Chitosan Sponge group.  The thermogel 
ejection force, approximately 20N, is significantly lower than comparable, previously 
studied chitosan paste formulations.  A preclinical, compatibility study of thermogel 
exposed to both hard and soft tissues demonstrated the paste to be capable of 
implantation for up to 7 days, inducing inflammatory responses similar to previously 
studied chitosan pastes.  No significant differences were found in the rate of clearance in 
a murine, polymicrobial defect, though average CFUs retrieved from explants were lower 
compared to control groups. Results indicate the thermogel is a compatible, degradable 
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Statement of Problem 
High-energy trauma to the musculoskeletal system can cause a complex wound 
characterized by lacerations and abrasions, open fractures, hematoma formation, and 
tissue necrosis [2-6].  The World Health Organization estimates traumatic injuries to 
the musculoskeletal system are the fourth leading cause of morbidity worldwide, 
responsible for five million annual fatalities [7, 8].  Unfortunately, the incidence of 
traumatic musculoskeletal injuries and accompanying morbidity is growing as the 
unsafe use of motorized vehicles increases in third-world and developing countries.  
Consequently, 95% of deaths related to traumatic injuries occur within low or middle-
income countries [7].  Reports have estimated if trauma care in under-developed 
socioeconomic countries was as established in “high income” countries, then two 
million lives could potentially be saved each year.  Even, a more conservative 
estimate states an 8% improvement in injury mortality rates in low and middle 
income countries would result in 400,000 lives saved annually [9].   
A primary contributor to morbidity and mortality associated with complex 
musculoskeletal wounds is the high risk of bacterial contamination, with infection 
rates ranging from 20% of civilian injuries [10-12] to 65% of orthopaedic trauma 
suffered [11, 13].  Necrotic tissue surrounding the wound experiences a diminished 
perfusion of bodily fluids, effectively restricting leukocytes and IV antibiotics from 
accessing the wound via vascular pathways [6].  Furthermore, the complex 
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morphology of a severe musculoskeletal wound can contribute to increased surface area 
that could allow for the adherence of invading planktonic bacteria, the initiating 
mechanism in the formation of biofilm [14, 15].  Biofilm is defined as bacteria 
attached to a surface, characterized by a self-produced matrix of exopolysaccharides, 
DNA, and proteins. The senescent nature of biofilm bacteria in addition to the 
exopolymeric matrix contributes to antibiotic resistance, with minimum inhibitory 
concentrations (MIC) up to 1000 times greater than the planktonic form [14-16].  
Biofilm-forming bacterial strains (i.e. Staphylococcus aureus, Pseudomonas aeruginosa) 
are among the most commonly identified species in complex musculoskeletal infections 
[17, 18].  Some biofilm-based infections can be eradicated with antibiotics administered 
systemically, but at dangerously high concentrations.  Antibiotics, especially 
glycopeptides such as vancomycin, can cause harm to the patient at high concentrations 
including nephrotoxicity and ototoxicity, among other ailments [19].   
Local antibiotic delivery systems have been designed to release inhibitory levels of 
antibiotic within the wound long enough to treat the infection while maintaining safe 
systemic concentrations [20-22].  Local antibiotic delivery devices can be applied as an 
adjunct treatment to the standard prophylactic method of IV delivery [20, 23].  Common 
biomaterials for local delivery systems include poly(methyl-methacrylate), calcium 
sulfate, and poly(glycolic-acid), among many others [23, 25, 30].  However, there are 
shortcomings that limit the efficacy of these materials as local antibiotics delivery 
vehicles, including degradation rates and potential toxicity of degradation products [24, 
19, 28].   
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The current report focuses on chitosan, a naturally derived, linear polysaccharide 
comprised of randomly dispersed glucosamine and N-acetyl glucosamine monomer units 
linked by glycosidic bonds in a β(1-4) pattern [24].  With a unique polycationic 
backbone, favorable compatibility, and bio-resorbable nature; chitosan has a wide 
range of medical applications. Additionally, many material characteristics such as 
degradation or drug release can be tailored via modification of the crystallinity, 
molecular weight, degree of deacetylation of chitosan, as well as chemical or physical 
crosslinking of synthetic additives [25-27].  Recent studies have demonstrated the 
feasibility of chitosan as a constituent of effective local antibiotic delivery systems in 
as the form of lyophilized chitosan sponges [28-33].  However, chitosan sponges may 
have limited efficacy preventing infection in complex musculoskeletal wounds due to 
an inability to conform to the complex morphology, as well as an initial burst release 
of the loaded antibiotics [34, 35].   
To address the limitations of chitosan in a sponge form, an injectable paste 
variation of finely ground, lyophilized chitosan hydrated with antibiotic loaded saline 
has shown to have potential as an effective infection-prevention tool within 
musculoskeletal wound trauma care [1, 36].  The present report will detail the 
fabrication of the experimental thermogel chitosan paste, formed by compositing with 
β-glycerophosphate (β-GP).  The resulting product is a thermo-responsive paste that  
undergoes a temperature-dependent gelation process as the paste approaches body 
temperature.  Following the fabrication, the investigation into the functional and 
clinical efficacy of thermogel is conducted via in vitro models of cytocompatibility, 
antibiotic release characteristics, enzymatic degradation, and injectability.  The 
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clinical potential of the paste is evaluated via preclinical studies of functional 
compatibility and antimicrobial efficacy.  
Hypothesis and Research Objectives 
It is hypothesized the thermogel chitosan paste formulation, containing β-
glycerophosphate (β-GP), will form a biocompatible, bio-resorbable, temperature-
responsive drug delivery polymer.  The thermogel will be capable of point-of-care 
antibiotic loading via hydration; exhibit favorable injectability at room temperature 
(20ºC) and subsequent in situ gelation as the environmental temperature rises to bodily 
levels (37ºC); and local, therapeutic release in vivo for at least 72 hrs.  The goal of the 
work reported in the current study is to develop a partially injectable infection-prevention 
tool to be used in trauma care, effectively reducing the incidence of morbidity associated 
with musculoskeletal wounds resultant of traumatic injuries.   
The research objectives can be broken into the functional and preclinical evaluations 
of the thermogel as a local antibiotic delivery device relevant in trauma care, assessed 
with respect to previously researched chitosan-based local drug delivery systems.  The 
functionality of the paste was evaluated via investigations into the paste cytotoxicity to 
murine fibroblast-like cells, in vitro antibiotic release profiles of the experimental 
samples dual-loaded with vancomycin and amikacin, and the rate of in vitro enzymatic 
degradation.  Material properties of the paste were investigated via studies of ease of 
ejection from a syringe, bio-adhesive characteristics, ability of the paste to conform to a 
representative wound bed, as well as a model of the antibiotic diffusivity from the paste 
into a narrow, deep, complex wound. Preclinical efficacy of the paste is evaluated via two 
5 
 
models: a functional biocompatibility model, and an antimicrobial efficacy model in a 




CHAPTER 2  
LITERATURE REVIEW 
Musculoskeletal Injury 
Damage inflicted to the soft, hard, and connective tissue of the musculoskeletal system 
can result in a superficial wound such as an abrasion, avulsion, or laceration; and can 
cause internal damage such as a fractured bone or torn connective tissue [37].  Globally, 
traumatic injuries are the leading cause of morbidity in individuals under 45, and the 
fourth leading cause among all age groups [8].  A 2007 investigation conducted by the 
World Health Organization into the rates of hospital admission for non-fatal traumatic 
injuries worldwide revealed the majority of all reported injuries involved the 
musculoskeletal system; “open wound” being the most frequently occurring resultant 
injury of the reported trauma [38].  The rate of traumatic injury as well as the mortality 
rate of these injuries are nearly double in low and middle-income countries compared to 
high-income countries such as the United States [39].  Additionally, the mortality rate is 
steadily rising due in part to increased use of motorized transport and the lack of proper 
trauma care systems throughout the majority of the world [40].  It has been estimated 
there are over five million traumatic injury-related deaths annually, with 95% of these 
deaths occurring within the low or middle income countries [7].  A report by Rivara et al. 
emphasized the socioeconomic differences in traumatic injury mortality rate by 
estimating that two million lives could potentially be saved each year if improvements in 
injury mortality rates in low and middle income countries reach the levels in developed 
countries [9]. Trauma care is a global healthcare concern and efficient, sustainable 
7 
 
strategies to provide orthopaedic trauma care is an important step in mitigating the 
impact of traumatic injuries [41]. 
The Wound Healing Process and Risks Associated with Musculoskeletal Trauma  
Injuries involving both blunt and penetrating trauma can damage the tissue of the 
musculoskeletal system in a non-uniform pattern and form an irregular wound bed 
topography.  Wounds of this nature are identified as complex, a term to describe 
wounds spanning multiple tissue types, often the result of devastating injuries, and 
requiring an extended healing time [2, 6, 42].   
Following coagulation, the early inflammation phase begins with the activation of 
the complement components which work to repair the wound beginning with the 
recruitment of phagocytic neutrophils to the site to destroy and remove foreign 
contaminants such as bacteria via the release of proteolytic enzymes and oxygen-
derived free radicals [3, 43].  The late inflammatory phase is characterized by the 
arrival of macrophages which work with neutrophils to debride the wound site, 
combat invading microorganisms, and provide essential tissue growth factors [44].  
At approximately 72h post injury, the inflammatory stage transitions to the 
proliferative phase, a multi-week process of tissue regeneration during which 
fibroblast cells migrate into the provisional matrix of fibrin and platelets and form 
new extracellular matrix referred to as granulation tissue.  The newly formed tissue 
consists of fibroblasts, macrophages, and vasculature-forming endothelial cells within 
a matrix of fibronectin, collage, and hyaluronic acid.  In complex traumatic wounds, 
these processes may be impaired or delayed due to vascular injury.  Impairment of 
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neutrophils or macrophages could lead to reduced phagocytosis of bacterial 
contaminants, which could in turn lead to infection and impaired healing[44-46].   
The jagged, irregular bed of a complex wound bed provides a sheltered region of high 
surface area that is very favorable for the proliferation of bacteria and biofilm formation.  
Penetrating trauma can incorporate contaminants such as clothing or sediment into the 
wound, increasing contamination and the risk of subsequent infection [2].  Adherence of 
planktonic bacteria to a surface leads to biofilm formation. Low metabolic activity of 
biofilm bacteria protects the encased bacteria from antimicrobial agents and immune cell 
attack [15, 16].  A study by Costerton et al. [14] of Pseudomonas aeruginosa revealed a 
1000-fold increase in the minimal inhibitory concentration of bacteria growing in 
biofilms compared to the planktonic counterparts. Stable biofilms can develop into 
densely populated networks of microorganisms which can detach and seed further sites of 
infection and can cause tissue destruction and systemic infection [15, 47] The presence of 
inflammatory agents induced by the biofilm causes an increased mutation rate of the 
microbes, which can contribute to the adaptation of the biofilm microbes by induction of 
antibiotic resistance and increased resilience [48].  The most common biofilm-producing 
organisms found in orthopedic infections are Staphylococcus aureus (Fig. 1), coagulase-
negative staphylococci, beta-hemolytic streptococci, and aerobic gram-negative rods, 






Figure 1: SEM photo of S. aureus exhibiting biofilm formation on an orthopaedic implant 




Complex musculoskeletal wounds suffered by civilians, often resulting from 
automobile accidents, have an estimated 20% chance of infection [10-12].  However, 
complex orthopaedic trauma suffered by soldiers in a combat situation exhibit an 
estimated 65% rate of infection [11, 13].  A large-scale bacteriological study by Carsenti-
Etesse et al. of 1000 patients being treated for open leg fractures provides evidence of 
bacterial contamination in traumatic wounds.  Cultures were obtained from open fracture 
wounds at the time of admission and again at various stages throughout the treatment 
process, categorized by the antibiotic used for treatment.  The wound contamination rate 
at the time of admission ranged from 26-30%, reaffirming the susceptibility of traumatic 
wounds to infection.  After 3 months of treatments the infection rate of patients ranged 
from 6.6-8%.  Additionally, there was a higher rate of antibiotic resistance in bacterial 
strains that had been cultured after systemic antibiotic treatment [49].  The results of open 
fracture epidemiology detailed by Carsenti-Etesse et al. demonstrate the high rate of 
initial contamination in open musculoskeletal wounds, the incidence of chronic infection 
regardless of systemic delivery, and the correlation between an increased rate of bacterial 
antibiotic resistance after IV antibiotic administration.  Results of the Carsenti-Etesse et 
al. study are in agreement with the findings of a 1974 clinical study by Patzakis et al. on 
the role of antibiotics in open fracture management.  For 10 days, the infection rate was 
investigated in the treatment of 333 open fractures treated with IV administration of 
cephalothin, a penicillin and streptomycin combination, or no antibiotic treatment at all.  
There was no statistically significant difference between the infection rates of the group 
receiving no antibiotics (13.9%) and the group receiving penicillin and streptomycin 
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(9.7%), while the group receiving cephalothin (2.3%) was significantly lower than 
those for the other two groups.   
The surgical closure of an infected traumatic wound may be delayed in order to 
allow the healing wound to gain resistance to infection and permit uncomplicated 
closure.  Johnson et al. demonstrated early closure in an infected wound causes the 
formation of weaker granulation tissue than infected wounds with delayed closings 
[50].  Patients with infected traumatic wounds typically undergo debridement of 
necrotic tissue followed by wound dressings.  The wound is left opened and 
undisturbed for the first 4 days while antibiotic therapy is administered intravenously.  
It is generally agreed upon that when the bacterial count of the tissue is lower than 105 
organisms/gram of tissue, treatment can proceed with a delayed closure without a 
major risk of infection [51].  There is a very small window of time between the injury 
occurring and the proliferation of bacteria to a level capable of developing an 
infection.  In the world of emergency trauma care, a 6 h delay in treatment is 
associated with a bacterial population estimate of 106 colony forming units of bacteria 
per gram of tissue [52].  A wound exposed without treatment for 3h normally develops 
a coagulum large enough to surround the bacteria in the wound and prevent contact 
with either systemic or topical antibiotics.  The exudate provides the opportunity for 
contaminating microbes to develop a resistance to delayed antibiotic care.  Therefore, 
IV administration of antibiotics is standard prophylactic treatment for patients who are 
believed to have contaminated wounds [5, 6].   
Vasculature damage in the affected tissue causes that creates a favorable 
environment for bacterial infection, since damaged vasculature limits access of 
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immune cells or intravenously administered antibiotics transported via cardiovascular 
vessels.  [10, 20].  Physiologically, antibiotics administered intravenous (IV) are 
ineffective in hypoxic tissue, as there is no flowing conduit for antimicrobial diffusion 
into the wound [53].  The bolus method of IV delivery creates a bioavailability profile of 
a sinusoidal nature in which high systemic levels are reached upon injection followed by 
a fast decline to ineffective levels until the next bolus delivery is administered.  The 
oscillating pattern of antibiotic levels could prove harmful to the wound healing process 
by strengthening the bacterial infection in the wound [54].  Antibiotics present at levels 
below the minimum inhibitory concentration in a bacterial infection can stimulate biofilm 
production as a mechanism of antimicrobial resistance.  Mlynek et al. investigated the 
biofilm production of methicillin-resistant Staphylococcus aureus exposed to sub-
inhibitory levels of amoxicillin compared to biofilm produced in the complete absence of 
antibiotics [55].  At the low amoxicillin levels, bacteria show an increased tendency to 
adhere to a surface and form a thick biofilm with a developed structured of channels and 
pillar and less porous than antibiotic-free biofilm.  Due to wound accessibility obstacles, 
systemic administration of IV antibiotics is not an efficient method of therapeutic 
delivery and an alternative method of delivery must be considered [23].  
Local Antibiotic Delivery Systems 
For musculoskeletal infections, local antibiotic delivery devices present the potential 
for an alternative or adjunct treatment option to the standard prophylactic method of 
systemic IV delivery.  Due to a steep concentration gradient, antibiotics passively diffuse 
from local areas of high antibiotic levels into avascular areas of wounds inaccessible by 
systemic antibiotics.  Biofilm-forming colonies of bacteria that would normally develop a 
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resistance to an antibiotic at lower levels experienced in systemic delivery, are 
vulnerable at a high local concentration [56].   
An ideally designed local antibiotic delivery system would provide an efficient 
delivery of high levels of antibiotics to the site of infection while the systemic 
concentration of antibiotics remained low to minimize the risks of systemic toxicity 
associated with the traditional method of IV antibiotic delivery [20].  As a system that 
will be implanted in the body for an extended amount of time, the biomaterial 
properties of the local drug delivery vehicles must be closely assessed to minimize the 
inflammation associated with foreign body response.  Properties commonly evaluated 
are cytotoxicity of the material, structural integrity of the scaffold, degradation of the 
scaffold, and the elution rates of antibiotics from the scaffold.  Antibiotic delivery 
vehicles can be divided into nonbiodegradable and biodegradable classes, and the 
degradable scaffolds can be categorized based on their properties and applications: 
bone graft and graft substitutes, synthetic polymers, and natural polymers [22, 57].  
Polymethylmethacrylate (PMMA) is a nonbiodegradable synthetic polymer used as 
an artificial bone cement in orthopedic surgery, and can also function as a local 
antibiotic delivery system [58-60]. Administered as beads, solid spacers, or 
intramedullary nails, antibiotics delivered through PMMA biomaterials can be used to 
treat  large hard or soft tissue defects [61, 62].  However, the clinical use of PMMA as 
a vehicle for local antibiotic therapy is not without its limitations.  There is a limited 
availability of antibiotics that are compatible with PMMA due to the physical and 
chemical requirements of the mixing process.  Water soluble antibiotics must be in 
powder form, chemically stable, and effective against a broad bacterial spectrum in 
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order to be added to PMMA during the hydration and mixing stage.  Since the exothermic 
polymerization of the cement can raise temperatures up to 80ºC, antibiotics used in bone 
cement systems must also be stable across a large range of temperatures [63].  
Gentamicin, tobramycin, and vancomycin are commonly used with bone cement [64].  
Since PMMA is a non-biodegradable local antibiotic delivery scaffold, the length of 
implantation as well as the method of implant removal are major concerns.  Prolonged 
implantation may catalyze the development of antibiotic-resistant bacteria despite killing 
bacteria during the elution phase.  However, bacteria can still persist once the elution 
phase has ended and the PMMA vehicle is perceived as a foreign body with antibiotics 
being released below therapeutic levels.  The foreign body creates a large surface for 
bacterial adherence and subsequent biofilm production, a known potentiator of antibiotic 
resistance in bacteria [65].  Many studies have investigated the negative effects of bone 
cement, including a report by Wininger et al. which correlated the increase in the 
prevalence of resistant bacteria with the introduction of antibiotic-loaded bone cement 
[66].  The surgical removal of PMMA implants within 4 to 6 weeks after implantation is 
recommended to avoid contamination and removal complications [67].   Degradability 
concerns with PMMA have directed the research and development of delivery systems 
towards an absorbable or biodegradable approach.  Antibiotics have been incorporated 
into bone autografts and allografts clinically for over 20 years [68].  Antibiotic powder 
can be combined with morselized cancellous bone or by submersion of the graft in an 
antibiotic solution [69].  A 1998 study by Chan et al. studied iliac cancellous bone grafts 
impregnated with piperacillin and vancomycin via submersion in solution [70], finding 
that infection clearance occurred at a rate of 94.4% and improved patient outcomes.  
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Composite materials can be substituted for bone autografts, including calcium sulfate, 
calcium phosphate, hydroxyapatite, and tricalcium phosphate.   No form of degradable 
local drug delivery system has been cleared by the Food and Drug Administration 
(FDA) [20, 71].  However, bone substitute materials have been approved for use in the 
repair of bony defects.  As an infection prevention method, the treating physician may 
mix the antibiotics into the bone graft substitute material when it is being mixed and 
hydrated as in the PMMA delivery systems.  Antibiotic-loaded calcium sulfate is the 
most commonly used bone graft substitute material in hard tissue reconstruction of 
osteomyelitis patients [72].  Its use as an antibiotic delivery system is in some cases 
preferred over PMMA beads since there is no removal surgery needed [68, 73].  
However, a faster degradation rate could be a cause for concern, leading to a rapid and 
variable antibiotic elution profile and a high rate of resorption which presents 
cytotoxicity issues [57].  Calcium sulfate has been shown to provoke an inflammatory 
response resulting in increased fluid in the wound bed and opaque drainage which can 
be perceived as the recurrence of infection [74].  The solid form of the material in bead 
form may also limit its usage in complex musculoskeletal wounds, as the irregular 
shape of the wound prevents the calcium sulfate beads or bone filler to properly 
distribute the antibiotics.   
The variability in elution and degradation properties of calcium sulfate has 
motivated the investigation into synthetic polymers as local drug delivery vehicles.  
Benefits of using synthetic polymers include the ability to predict and modify several 
aspects of the local antibiotic delivery, as well as the opportunity to create a 
composite-therapeutic delivery system of more than antibiotics, such as growth factors 
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to promote tissue regeneration or cytokines to attract specific cells or extracellular 
proteins [57].  Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and their respective 
copolymers are the most common synthetic degradable polymers in medicine [75], and 
can be advantageous as drug delivery systems due to the gradual degradation 
demonstrated at physiological pH.  The elution of the loaded antibiotic from some 
synthetic polymers can be adjusted by varying the monomeric composition, crystallinity, 
and molecular weight [21].  PLA and PGA implants elicit minimal inflammatory 
responses which subside as the polymer is gradually absorbed [76].  Another benefit is 
the wide range of antibiotics compatible with synthetic polymers for in vivo release for a 
definite time period at an effective concentration [77].   
Recently, research has focused on the development of a bioabsorbable gel as an 
antibiotic delivery vehicle capable of releasing all carried antibiotics as it degrades and 
provides a uniform distribution of antibiotics throughout the wound as opposed to 
discrete pockets around PMMA or calcium sulfate beads.  A 2014 report by Penn-
Barwell et al. [22] details the 14 day treatment of an open femoral defect in a rat model 
inoculated with S. aureus via application of a bioabsorbable phospholipid gel loaded with 
both vancomycin and gentamicin or PMMA beads loaded with vancomycin or 
tobramycin.  The gel demonstrated complete wound coverage and a significantly lower 
infection rate than the PMMA beads; authors concluded it to be a novel and effective 
option for a local antibiotic delivery.  Recent advances in additive manufacturing 
technology have motivated the need for printable gels capable of structural support for 
the production of tissue engineering scaffolds via layered deposition [78].  Limitations of 
synthetic polymers include the loss of structural integrity as the polymer degrades 
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throughout treatment as well as the relatively low supply of synthetic polymers cleared 
for use in the medical field [20].   
Natural polymers are advantageous for local delivery in part for the ability to be 
degraded due via in vivo enzymes and metabolic pathways, resulting in minimal 
foreign body response from the host [79].  Yet clinical issues are still presented by 
natural polymers such as immunogenicity, lot-to-lot variability, molecular complexity, 
and inadequate mechanical properties [80].  .  Naturally derived materials commonly 
implemented within the biomedical field include alginate, collagen, fibrin, and 
chitosan.  Alginate is a material constituted of linear, anionic polysaccharides derived 
from kelp or algae, and can be cross-linked by various agents to form a hydrogel, a 
term referring to a hydrophilic polymer with a very high-water content.  Since alginate 
is foreign to mammalian cells, the polysaccharide chains making up the alginate 
molecule cannot be naturally broken enzymatically in vivo, resulting in compromised 
degradation control.  Alginate hydrogels can be tailored to be used as drug delivery 
vehicles, among many other applications, and have been approved by the FDA as a 
topical wound dressing capable of providing a microbial barrier in some products [81].  
The most widely researched natural biodegradable polymer is collagen.  The structural 
protein which accounts for over 90% of all fibrous proteins in animals is present in 
virtually every type of tissue, resulting in an absorbable, biocompatible implant that 
does elicits minimal foreign body response.  Collagen can be chemically modified via 
numerous documented cross-linking methods [82].  The chemical modifications alter 
material properties which coincidentally can be manipulated to tailor the collagen to 
specific therapeutic applications.  Modifying a collagen sponge with increased 
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intermolecular crosslinks will decrease susceptibility to enzymatic degradation, decrease 
solubility in aqueous solutions, and increase tensile strength, among many other effects.  
Therefore, drug delivery characteristics such as antibiotic release and in vivo degradation 
rate can be indirectly tailored [83, 84].    A 2013 study by Chang et al. investigated the 
diagnoses of approximately 7000 orthopaedic surgery patients treated with gentamicin-
loaded collagen sponges to prevent bacterial contamination at the surgical site an did find 
a decreased  rates of surgical site infection [85].  
It is important to note the compatibility benefits of natural polymers while also 
considering the negatives such as batch variability and poor mechanical qualities.     
Engineering composite blends of natural polymers is an approach to overcoming some of 
the limitations of natural polymers, while preserving the natural cytocompatibility.    A 
2014 report by Doty et al. [86] describes an extended in vitro release of vancomycin and 
growth factors from a biodegradable composite bone graft constituted from calcium 
sulfate embedded with chitosan microspheres.   
An Introduction to Chitosan 
Naturally occurring in the exoskeletons of crustaceans such as crab and shrimp, chitin 
is the most abundant amino polysaccharide on earth.  Capable of being sustainably 
recycled from food processing plants, chitin is then subject to multiple refinement 
processes, including an acid decalcification and an alkaline treatment to remove all 
proteins [87].  The molecular structure of chitin is then de-acetylated in a reaction with a 
strong alkali under high temperature and pressure.  The resulting product is a variable 
chain polymer characterized by a random distribution of glucosamine monomers 
containing positively charged free amino groups (Fig. 2) [88, 89]. Chitosan and chitin are 
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terms referring to the same linear polysaccharide, compromised of a repeating chain of 
glucosamine and N-acetyl glucosamine monomers linked in a β(1-4) glycosidic bond 
pattern [24].  The degree of deacetylation (DDA) of a batch of chitosan describes the 
ratio of glucosamine to N-acetyl glucosamine units in the polymer.  A DDA of 50% or 
greater constitutes the “chitosan” nomenclature and less than 50% is termed “chitin” 
[90, 91].  Most commercially produced chitosan has a DDA ranging from 70 to 95% 
and a relatively high molecular weight ranging from 300 to 1000 kDa, properties 
which can affect the applications of chitosan [92].  Chitosan is insoluble in neutral and 
basic solutions.  However, in dilute acidic solutions pH6, the glucosamine monomers 
dissociate from the polymeric chain facilitated by the protonation of the free amino 
groups; solubilizing the polymer into a slightly acidic, viscous solution [93].  The pH 
responsive phase change of chitosan makes it possible to process chitosan into several 
forms that correspond to a host of different medical applications; examples include 
tissue engineering scaffolds [94], nanoparticles [95], microparticles [96], nanofibers 





Figure 2: process of chitin deacetylation into chitosan; chitosan is a linear polymeric 





     
The physiological interaction between an implant and the host must be considered 
during the design process, particularly so in the case of a drug delivery vehicle.  One 
of the most important considerations is the magnitude of the host response to the 
foreign body, normally characterized by acute inflammation in almost all surgeries 
involving implant.  A non-degradable biomaterial will almost always require a 
removal surgery, potentially with moderate risk, to avoid the inevitable foreign body 
reaction from the host immune system that would end up harming the host.  After the 
acute inflammation stage has passed, and both the polymorphonuclear cells and 
macrophages have failed to phagocytize or encapsulate the nondegradable implant in 
fibrous tissue, the macrophages will begin to release reactive oxygen species (ROS) 
[101].  ROS can cause significant damage to the surrounding microenvironment by 
oxidizing amino acids, deactivating vital enzymes, or damaging the DNA of the 
surrounding cellular population [102, 103].  Macrophages can be triggered to release 
ROS in the presence of degradable implants as well, whether the implant cannot 
degrade fast enough, or the degradation products might still be harmful to the host.  
Chitosan can be easily metabolized by the host immune system through several 
mechanisms including both chemical and physical forces breaking apart the 
biopolymeric chain.  The main driver of chitosan degradation is hydrolysis catalyzed 
by lysozyme, an enzyme found throughout the body, including macrophages, as 
detailed by Nordtveit et al. [104].  Lysozyme acts by catalyzing the hydrolysis 
reaction of chitosan, cleaving the glycosidic bonds of the polymeric chain into 
glucosamine and saccharide byproducts, which can be further phagocytized by or 
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proteoglycans [105, 106].  There is an abundance of reports lauding chitosan for its 
properties that make it an optimal biomaterial for therapeutic delivery (i.e. 
biocompatible, mucoadhesive, biodegradable, antimicrobial) [90, 107].  As a naturally 
derived polymer, chitosan implants provoke minimal foreign body responses; 
demonstrated in a study by VandeVord et al. [108].  Porous chitosan scaffolds were 
subcutaneously implanted into murine host subjects for up to 12 weeks.  Authors noted 
the chitosan scaffolds did not warrant any pathological inflammatory responses for the 
duration of the study; evidence which further supports biocompatibility of chitosan, even 
over a relatively long time period.  
Chitosan is a mucoadhesive biomaterial, explained by the strong electrostatic force of 
the cationic amine groups lining the backbone of chitosan to the anionic mucins, 
glycosylated proteins highly concentrated on mucosal tissue surfaces such as pulmonary, 
corneal, intestinal, and gastric mucosal tissues, described in a report by Karn et al. [109].  
In addition to agreeing with the findings by Kart et al, Sogias et al. reported the 
mucoadhesion observed in chitosan can be partially explained by the hydrogen bonding 
between the chitosan and the mucosal membranes [110].  Mucoadhesion contributes to 
chitosan adherence to a musculoskeletal wound via anionic molecules in the 
musculoskeletal tissue, such as the anionic proteoglycans comprising connective tissue 
[111]. 
Chitosan for Drug Delivery 
Chitosan is a versatile biomaterial with many applications and forms, such as 
membranes loaded with growth factors to facilitate periodontal bone regeneration [112] 
and hemostatic wound dressing containing natural coagulants, used in combat trauma 
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care [113].  A preliminary study of chitosan sponges loaded with vancomycin and 
amikacin, revealed that both antibiotics were released at therapeutic concentrations for up 
to 72 hours [25].  In several recent studies, efficacy of chitosan sponges as 
biocompatible delivery devices has been demonstrated in preclinical models [25, 33, 
114-116].  Chitosan sponges blended, modified, or crosslinked with composites have 
shown to improve drug delivery properties of the devices, including biocompatibility, 
degradation, or the antibiotic release kinetics [117-120] .  A 2015 report by Parker et 
al. of the addition of PEG to the formulation of chitosan sponges, loaded with 
amphotericin B and vancomycin, increased degradation rates and improved the in 
vitro biocompatibility compared to neutral sponges containing only chitosan [27, 
121].   
Another additive of interest is β-glycerophosphate (β-GP), a slightly basic anionic 
molecule that creates a polyelectrolyte complex with the chitosan molecules [122].  
The force of attraction resulting in the polyelectrolyte complexation between chitosan 
and β-GP has been observed as similar to the interaction between chitosan and 
commonly used ionic cross-linkers such as Fe(III) [123]. When formulated as a 
hydrogel, chitosan and GP are very fluid, or non-viscous, at room temperature (20°C) 
and as the surrounding temperature is increased to the approximate value of body 
temperature (37°C) the chitosan/GP mixture undergoes a non-reversible gelation 
[124]. It has been observed that as temperature increases, the ionic activity of GP 
increases leading to a higher density of ionic bridges between chitosan and GP that can 
explain the gelation [122, 125]. A 2007 study by Ahmadi et al. [126] investigated both 
the in vitro gelation time and cytocompatibility of chitosan-GP hydrogel formulations 
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characterized by varying chitosan content between 0.5-2% (wt/vol) and GP content 5-
20% (wt/vol) in 0.1M hydrochloric acid. Results revealed as chitosan and GP content 
increased, the in-situ gelation time decreased. An increase in GP content adversely 
affected the in vitro cytocompatibility, while the chitosan actually improved 
biocompatibility as the mass content rose to 2%. It was concluded that hydrogels 
containing no more than 10% GP (wt/vol) were cytocompatible and appropriate for use 
as a drug delivery system.  A report by Ruel-Gariepy et al. [127] reviewed 
thermosensitive hydrogels containing chitosan and GP to be implemented as drug 
delivery devices. The authors deemed chitosan-GP hydrogels suitable for sustained drug 
delivery based on results of drug elution profiles, noting that drug release profiles 
improved with an increased GP content. The hydrogel delivery system can be loaded with 
a wide range of drugs, including antibiotics, based on the fact that the electrostatic charge 
of the loaded model drug compound had no effect on the release characteristics. 
Additionally, authors observed the gelation rate was dependent on the temperature and on 
the chitosan deacetylation degree, and the solution containing 84%-deacetylated chitosan 
could be stored 3 months at 4°C without apparent change in viscosity or adverse effects 
to physio-chemical properties.  
Research Narrative 
Over the course of recent investigations into the feasibility and refinement of chitosan 
paste, clinical potential as an effective point-of-care, infection prevention tool in trauma 
care has been demonstrated.  Previous studies provide insight into the effect of altering 
specific parameters of the paste formulation.  Smith et al. detailed the original 
investigation of chitosan paste [128] and demonstrated the effects of acetic acid 
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concentration ((0.05M or 0.15M acetic acid) on paste properties.  In vitro studies 
proved that the paste made with a lower acetic acid concentration had a more effective 
antibiotic elution profile, extended degradation time, as well as more favorable 
injectability and adhesion qualities.  However, there were major limitations in in vivo 
biocompatibility; exhibited by subject morbidity in a functional biocompatibility 
model involving implants in an intramuscular back model in rat subjects.  The paste 
formulation was changed to a 50:50 ratio of neutral to acidic chitosan components to 
address compatibility issue.  
A study by Rhodes et al. investigated the efficacy of a chitosan composite paste 
blended with PEG and incorporated with neutral chitosan particulate [1].  The neutral 
to acidic chitosan mass ratio varied among experimental groups: 2:3, 1:1, and 3:2.  All 
paste formulations exhibited degradation, antibiotic elution, and bio-adhesion; 
however, the 2:3 neutral to acidic ratio paste was deemed significantly less 
compatibility to the evaluated cell culture  in vitro than the other experimental groups.  
The paste proved effective in preventing bacterial contamination in a subcutaneous S. 
aureus infected murine catheter model. It was concluded the paste with a 1:1 ratio of 
neutralized chitosan/PEG to acidic chitosan dry mass was the optimal group for local 
antibiotic delivery, based on a longer degradation time and extended elution profile 
over 72 hours [1]. 
Beretta et al. investigated the feasibility of a completely acidic chitosan paste in 
which the acetic acid concentration of the chitosan/PEG paste was solubilized in 
0.85% (vol) acetic acid, as opposed to combining acidic and neutralized dry 
components to reduce processing time and improve biocompatibility [36].  The fully 
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acidic chitosan hydrated paste resulted in a material more homogenous than the chitosan 
paste investigated previously by Rhodes et al. [1].  Additionally, the effect of changing 
the ratio of chitosan to PEG was investigated by creation of experimental groups that 
were made with either a 1% chitosan/1% PEG (8kDa) formulation or a 1% chitosan/0.5% 
PEG (8 kDa) formulation. Results of the study indicate that an increased PEG content 
significantly increases the rate of paste degradation, and therefore the rate at which 
antibiotics are released.  Additionally, the fully acidic paste exhibited a significantly 
lower force of ejection from a modified syringe, and a decreased time of adhesion to the 
tissue.  The chitosan/PEG paste formulation with 1% chitosan and 0.5% PEG content was 
deemed to have more suitable characteristics for a local drug delivery device.   
The current report further explores the effect of different additives, acetic acid content, 
as well as the incorporation of neutral chitosan particulate into the formulation.  The goal 
of a new paste formulation was to improve wound coverage, drug delivery 
characteristics, injectability, and biocompatibility.  Therefore, the formulation was 
designed as an equal combination of acidic chitosan composited with a β-
glycerophosphate additive and neutral chitosan particulate.  The addition of the 
composite β-glycerophosphate to chitosan hydrogels has been shown to create a 
temperature-sensitive gelation process as the temperature is increased.  It was theorized 
that a chitosan paste composited with β-glycerophosphate would create a thermo-
responsive polymeric drug delivery system, in which the paste has a low viscosity at 
room temperature and a higher, gel-like viscosity as the temperature is increased to levels 
similar to the human body.  A low viscosity paste is favorable for injectability from a 
cannula syringe tip, and more importantly improved wound coverage; allowing the 
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antibiotic loaded polymer to seep into the crevices of the complex wound bed.  The 
improved wound coverage decreases the distance between the antibiotics and the 
bacterial contaminations, resulting in an improved antimicrobial efficacy.  The model 
of the drug delivery system is based off the concept of polymeric drug delivery 
systems containing two types of material in which one degrades quickly and releases 
the other material which degrades much slower and can deliver drugs for a longer 
period of time.  In an attempt to further reduce the paste toxicity, the acidic portion of 
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Complex musculoskeletal wounds, resultant of high-energy trauma, are a 
leading cause of morbidity worldwide due, in part, to a propensity for bacterial 
contamination.  This work details the fabrication of a thermo-responsive, 
injectable chitosan composite paste by including the additive β-glycerophosphate, 
which creates a polyelectrolyte complex with the chitosan molecular backbone.  
Functional and clinical efficacy evaluations as an infection prevention treatment 
were determined within the scope of complex musculoskeletal wounds.  Findings 
from in vitro studies support the capability of chitosan paste to be loaded with 
dual antibiotics for release of inhibitory levels of both amikacin and vancomycin 
for at least 3 days. Further, rates of enzymatic degradation of approximately 60% 
of the initial mass were observed within 7 days.  The cytocompatibility of the 
thermogel is an area which requires improvement; eliciting the lowest cell count 
among all experimental groups, approximately 77% of the Control Chitosan 
Sponge group.  The thermogel ejection force, approximately 20N, is significantly 
lower than comparable, previously studied paste formulations.  A preclinical, 
compatibility study of thermogel exposed to both hard and soft tissues 
demonstrated the paste to be capable of implantation for up to 7 days, inducing 
inflammatory responses similar to previously studied chitosan pastes.  In the 
murine, polymicrobial defect model, the average CFUs retrieved from explants in 
the thermogel group was lower when compared to control, although no significant 
differences were present in bacterial clearance rate. Results indicate the thermogel 
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is a compatible, degradable biomaterial capable of therapeutic, local antibiotic release for 
up to 7 days. 
 
Keyword: chitosan, local antibiotic delivery, biofilm, complex musculoskeletal 





High-energy trauma to the musculoskeletal system can cause a complex wound 
characterized by lacerations and abrasions, open fractures, hematoma formation, and 
tissue necrosis [2-6].  The World Health Organization estimates traumatic injuries to 
the musculoskeletal system are the fourth leading cause of morbidity worldwide, 
responsible for five million annual fatalities [7, 8].  Unfortunately, the incidence of 
traumatic musculoskeletal injuries and accompanying morbidity is growing as the 
unsafe use of motorized vehicles increases in third-world and developing countries.  
Consequently, 95% of deaths related to traumatic injuries occur within low or middle-
income countries [7].  Reports have estimated if trauma care in under-developed 
socioeconomic countries was as established in “high income” countries, then two 
million lives could potentially be saved each year.  Even, a more conservative 
estimate states an 8% improvement in injury mortality rates in low and middle 
income countries would result in 400,000 lives saved annually [9].   
Complex musculoskeletal wounds are highly susceptible to bacterial 
contamination, with infection rates ranging from 20% of civilian injuries [10-12] to 
65% of orthopaedic trauma suffered [11, 13].  Necrotic tissue surrounding the wound 
experiences a diminished perfusion of bodily fluids, effectively restricting leukocytes 
and IV antibiotics from accessing the wound via vascular pathways.  The wound 
forms a sheltered, anaerobic environment favorable for bacterial proliferation [6].  
Furthermore, the complex morphology of a severe musculoskeletal wound can create 
a high surface area easily allowing for the adherence of invading planktonic bacteria, 
the initiating mechanism in the transformation to biofilm, which can be resistant to 
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antibiotics [14-16].  Biofilm-forming bacterial strains (i.e. Staphylococcus aureus, 
Pseudomonas aeruginosa) are among the most commonly identified species in 
complex musculoskeletal infections [17, 18].  Some biofilm-containing infections can be 
eradicated with antibiotics administered systemically, but at dangerously high 
concentrations.  Antibiotics can cause harm to the patient at high concentrations 
including nephrotoxicity and ototoxicity, among other ailments [19].  Local delivery 
devices used as an adjunct to the standard prophylactic antibiotics may provide biofilm-
eradicating levels of antibiotic to local tissue without systemic concentrations reaching 
dangerous levels [20-23].   
The natural biopolymer chitosan, comprised of randomly dispersed glucosamine and 
N-acetyl glucosamine monomer units linked by glycosidic bonds in a β(1-4) pattern [24], 
demonstrates favorable characteristics for local drug delivery, including compatibility, 
and bio-resorbable nature. Additionally, many material characteristics such as 
degradation or drug release are tailorable by altering the crystallinity, molecular weight, 
degree of deacetylation of chitosan, as well as chemical or physical crosslinking of 
synthetic additives [25-27].  Lyophilized chitosan sponges are capable of local, 
therapeutic antibiotic release [28-33]but have limited ability to conform to complex 
morphologies, as well as an initial burst release of the loaded antibiotics [34, 35].   
To address the limitations of chitosan in a sponge form; an injectable, paste variation 
of finely ground, lyophilized chitosan hydrated with antibiotic loaded saline has been 
developed and shown potential as an effective infection-prevention tool within 
musculoskeletal wound trauma care [1, 36].    By modifying the paste composition to 
include beta-glycerophosphate (β-GP) a thermogel material can be formed [35].  Neutral, 
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lyophilized chitosan particulate is incorporated into the formulation in an attempt to 
improve the biocompatibility and drug release characteristics of the paste; qualities 
described in a report by Rhodes et al. [34].      
The goal of the work reported in the current study is to develop an infection-
prevention tool to be used in trauma care; effectively reducing the incidence of 
morbidity associated with musculoskeletal wounds resultant of traumatic injuries.  It 
is hypothesized thermogel chitosan paste formulation will form a biocompatible; bio-
resorbable; temperature-responsive drug delivery polymer; capable of point-of-care 
antibiotic loading via hydration with antibiotic loaded saline and local, therapeutic 
release in vivo for at least 72 hrs.  The objective of this study is to determine 
preclinical efficacy of thermogel paste, including cytocompatibility, antibiotic release 
characteristics, enzymatic degradation, and injectability.  Preliminary in vivo efficacy 
of the paste  is evaluated via preclinical studies of functional compatibility and 
antimicrobial efficacy over a 7-day time period.   
Experimental 
2.1 Materials  
Chitopharm™ S chitosan powder (825±1.7 % DDA, 251 kDa) is produced by 
Chitopharm (Tromsø, Norway).  Poly(ethylene-glycol) (8kDa), vancomycin, 
amikacin, and Avertin (2, 2, 2-Tribromoethanol) are from Sigma Aldrich (St. Louis, 
MO, USA).  β-Glycerophosphate, Disodium Salt, Pentahydrate (β-GP), (306.1Da, 
CAS 13408-09-8 Calbiochem), as well as the dialysis membranes (pore diameter 
100µm) used in the elution studies are from EMD Millipore (Billerica, MS, USA).  
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The 4.5L benchtop lyophilizer is made by LabConco (Kansas City, MO, USA).  
Phosphate buffered saline, Cellgro Dulbecco’s modified eagle medium containing L-
glutamine and sodium pyruvate, fetal bovine serum, high performance liquid 
chromatography (HPLC) mobile phase components, and the spectrofluorometric 
amikacin detection method reagents are purchased via Fisher Scientific (Hampton, NH, 
USA).   Normocin is acquired from InvivoGen (San Diego, CA, USA).  NIH3T3 cells, as 
well as the bacterial strains of Staphylococcus aureus (ATCC #12598) and Pseudomonas 
aeruginosa (ATCC #27317) are supplied by the America Type Culture Collection 
(Manassas, VA, USA).  The Cell Titer-Glo® assay is manufactured by Promega 
(Madison, WI, USA).  The Synergy™ H1 plate reader is made by BioTek, (Winooski, 
VT, USA).  The Dionex UltiMate 3000 HPLC, the Hypersil Gold C18 column for 
vancomycin detection, as well as the 125-mL plastic Nalgene® containers are purchased 
from Thermo Fischer Scientific (Waltham, MA, USA).   The lysozyme enzyme (Type 
VI) is purchased from MP Biomedicals (Santa Ana, CA, USA).  Metal, porous 
hemispheres from Norpro (Everett, WA, USA).  The small bore (diameter 2mm) 10mL 
syringes are from BD™ (Franklin Lakes, New Jersey, USA).  The large bore syringes 
(7mm diameter) are from Qosina (model C1105; Ronkonkoma, NY, USA).  The 
compressive strength testing machine (Instron 33R Universal Testing Machine 4465, 5kN 
load cell) and operating software (Bluehill v2.13) are products of Instron (Norwood, MA, 
USA).  The male Wistar rats, strain code 003, are from Charles River North America 
(O’Fallon, MO, USA).  Gelfoam® porcine gelatin sponges are products of Pfizer 
Manufacturing (Puurs, Belgium).  Rimadyl is purchased from Zoetis (Parippany, NJ, 
USA).  The OSTEO16 imaging software is a product of BIOQUANT (Nashville, TN, 
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USA).  The histology scanner and microscope camera are manufactured by Nikon 
Instruments Incorporation (Melville, NY, USA).  ImageJ image analysis software, as well 
as 6 week old male mice C57BL/6 are supplied by the National Institute of Health 
(Rockville, MD, USA).  Graphical representations and statistical analysis of data is 
performed via GraphPad Prism 7.2, a program created by GraphPad Software 
Incorporation (La Jolla, CA, USA).  
2.2 Fabrication 
The experimental and control groups of antibiotic delivery devices are 
characterized by the content of chitosan, additives, acetic acid solution, as well as the 
presence of a neutralization step (Table 1).   The chitosan paste formulation 
containing β-GP, termed “thermogel”, is evaluated with respect to control groups of 
neutral, lyophilized chitosan.  For the cytotoxicity, antibiotic elution, and enzymatic 
degradation studies the neutral chitosan control group was investigated in two forms: 
lyophilized sponge coupons (8mm diameter) referred to as “Control Sponge” (Fig. 
1D) and a particulate made from finely ground lyophilized sponges named “Control 
Particulate” (Fig. 1E).  A chitosan paste composited with poly(ethylene-glycol) 
(PEG) is included in studies as a benchmark control group, as it was previously 




Table 1: Experimental chitosan group formulations. 
 
Experimental Group chitosan (wt) acetic acid (vol) additive (wt) pH 
1. Control Chitosan 1% 1% - neutral 
2. PEG paste 1% 0.85% 0.5% PEG acidic 
3. Thermogel 
50% Control Chitosan Particulate 




Figure 1A-F: Flowchart detailing the fabrication process of chitosan drug delivery 
devices; A. chitosan being solubilized in acetic acid solution; B. chitosan sponges rinsing 
with deionized water and pH monitoring during neutralization process; C. chitosan cast 
molds being lyophilized into sponges; D. neutral chitosan sponge (left), finely ground 
chitosan particulate (right); E. hydration of paste via antibiotic-loaded saline; F. chitosan 




Control chitosan sponges were fabricated by dissolving 1g of chitosan in 100mL of 
aqueous solution containing 1% (vol.) acetic acid. After mixing, solution was cast and 
frozen overnight at -80°C, and then lyophilized in a 4.5L benchtop lyophilizer at -50°C, 
with a minimum vacuum pump displacement of 86L/min (Fig. 1C).  At this step, 
lyophilized sponges are highly porous and solubilize in aqueous environments into a 
slightly acidic solution, referred to in the report as “acidic” chitosan  
A portion of the acidic sponges are then neutralized via an acid-base reaction 
described by Rhodes et al. [34], in which a strong base donates an electron to the 
protonated amine groups constituting the chitosan backbone.  The sponges are again 
frozen overnight at -80°C then lyophilized into the control neutral lyophilized sponge, 
which is then ground into a particulate form.  Hydration of the control groups requires 
120mg of dry mass mixed with 1mL of PBS.   
The thermogel chitosan paste formulation was fabricated by combining equal parts 
acidic, thermo-responsive chitosan composited with β-GP and neutral chitosan particulate 
described previously.  Fabrication of the acidic portion of the thermogel sponges were 
fabricated by dissolving 10g of β-GP and 2g of chitosan in 100mL aqueous solution of 
0.5% (vol.) acetic acid.  The solution ws then cast into molds, frozen overnight at -80°C, 
lyophilized, and ground into particulate via a blade grinder.  Prior to hydration, the acidic 
and neutralized chitosan components are combined in a 1:1 ratio by dry mass.  The 
thermogel is hydrated at the same ratio as the control groups, 120mg of dry mass per 
1mL of PBS.  The resultant paste is a temperature sensitive polymer with a very low 
viscosity at room temperature (20°C), and as the surrounding environment increases to 
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approximately body temperature (~37°C), it undergoes a gelation process, resulting 
in a more viscous paste material.  
The PEG Paste is a benchmark experimental group previously investigated by 
Berretta et al. [33].  Briefly, 500mg of PEG and 1g of chitosan was dissolved in 
100mL of 0.85% (vol.) acetic acid.  Freezing and grinding were conducted in a similar 
manner to other groups.  PEG Paste was hydrated by mixing 133mg of dry mass with 
1mL of PBS; resulting in a homogenous, acidic paste, as it does not undergo the 
neutralization process as the control groups do.  
2.3 Cytocompatibility 
In a cytocompatibility model described by Parker et al. [36], NIH3T3 cells were 
seeded onto a 24-well plate at a density of 2*104cells/cm2 in 1mL of cell culture media 
consisting of High Glucose Dulbecco’s Modified Eagle Medium, 10% (vol.) fetal 
bovine serum and 0.1 mg/mL Normocin.  Twenty-four hours post seeding, cell culture 
media was gently aspirated and replaced with 1 mL of fresh culture media. The 
Control Sponge and Particulate (120mg), PEG Paste (133mg), and thermogel (120mg) 
samples hydrated with 1mL of sterile filtered phosphate buffered saline (PBS, 1X) are 
added to porous (diameter 8µm) cell culture inserts (n=3, diameter 8µm), placed in the 
wells seeded with the NIH3T3 cells, and incubated (37ºC) for 72 hours.   
The viability of NIH3T3 cells was quantified via the Cell Titer-Glo® assay, and 




2.4 Antibiotic Elution and Activity 
Experimental samples (n=3, 133mg PEG Paste, 120mg Control Sponge, Control 
Particulate, thermogel) were hydrated with 1mL of sterile 1X PBS loaded with 
vancomycin (10mg/mL) and amikacin (10mg/mL).  Samples were inserted into cell 
culture crowns fitted on the bottom with dialysis membranes (diameter 100µm) and 
submerged in 8mL of sterile 1X PBS in a 6-well cell culture plate (Fig. 2), and gently 
shaken in an incubator at 37°C throughout the 7-day study.  Eluate samples (2mL) were 
collected every 24hrs and frozen (-80ºC); the remaining elution solution was gently 
aspirated and replaced with 8mL of sterile 1X PBS.  
Vancomycin levels in the eluate samples were measured via HPLC in a method 
derived from multiple glycopeptide detection protocols [37-39].  Peaks were detected at 
250nm UV, with a retention time of 1.6 min, using a C18 column 150mm x 4.6mm 
column in a mobile phase of 70% phosphate buffer (0.124M KH2PO4 and 0.08M 
K2HPO4) and 30% acetonitrile (CH3N) at a flow rate of 1 mL/min.   
Amikacin concentrations were measured using a spectrofluorometric protocol to detect 
aminoglycosides, described by Omar et al. [40]. Briefly, eluate samples were diluted ten-
fold, and reacted with a reagent of acetylacetone and formaldehyde in a buffer solution 
containing boric, acetic, and phosphoric acid titrated to a pH of 2.7.  The absorbance 
values of the reacted product at 450nm were measured with a SynergyTM H1 plate reader 
and calibrated to known amikacin concentrations. The measured antibiotic concentration 
of the eluates is supported via zone of inhibition (ZOI) analysis, following a protocol 
described by Ericcson et al. [41].  S. aureus and P. aeruginosa are chosen as 
representative bacterial strains because they are among the most commonly detected 
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bacterial strains in infected musculoskeletal wounds, and capable of forming biofilm 
[42]. Trypticase soy broth (TSB) agar plates were inoculated with either Staphylococcus 
aureus (ATCC 12598) or Pseudomonas aeruginosa (ATCC 27317).  Blank paper 
discs (diameter 6mm) were hydrated with antibiotic eluate samples (30μl), placed on 
the inoculated TSB agar plates, and incubated (37°C) overnight.  Plates were imaged, 







Figure 2A-B: Depiction of antibiotic elution study setup featuring a 6-well plate filled 






The degradation characteristics of the thermogel chitosan paste are assessed as the 
reduction in the dry mass during submersion in a lysozyme solution over a 7 day 
durations, based on the enzymatic degradation of chitosan by lysozyme [43].  The 
initial dry mass of experimental samples was recorded, (n=3/time point; 240mg 
Control Sponge, Control Particulate, and thermogel samples, 267mg PEG paste).  The 
samples were hydrated with 2mL of PBS; placed in porous (diameter 1.5mm), metal 
hemisphere containers; and restrained to the containers via a para-film cap sealing the 
container opening. The porous vessels containing the experimental samples are 
submerged in 40mL of lysozyme solution (Lysozyme Type IV, 1mg/mL), para-film 
side down in 125-mL plastic Nalgene® containers, and gently shaken in an incubator 
(37°C) for the duration of the study.  Every 48 hours, the lysozyme solution was 
gently aspirated from the containers and completely replaced.  On days 1, 3, 5, and 7 
the experimental samples (n=3/time point) were retrieved from the solution, dred 
overnight in a vacuum oven (80°C), and the mass was recorded. Percent of initial mass 
remaining was calculated via equation (1).  
Percent of Initial Mass Remaining (%) =
Final Sample Mass (mg)
Initial Sample Mass (mg)





Figure 3A-B: (A) degradation model materials including the porous hemisphere, para-
film cover, and 125mL containers; (B) experimental sample in porous hemisphere 






 The force of ejection was assessed by ejecting 5mL experimental samples 
(n=3) of the PEG paste (667mg) and thermogel paste (600mg) from a 10mL syringe 
(bore diameter 2mm) and a 15mL large bore syringe (diameter 7mm).  Syringes were 
fixed in a compression testing machine depressing the plunger at a rate of 1mm/sec 
until the paste was completely ejected (Fig. 4A-B).  The injectability was quantified as 
the maximum reactive force of the syringe plunger against the compressive load cell 
as the 5mL paste samples are ejected.  As a benchmark value to represent a relevant 
ejection force, volunteers (n=10) were asked to depress the plunger of a 10mL syringe 
modified with a load cell to measure the pressure. The benchmark value of ejection 





Figure 4A-B: Experimental paste samples being ejected from (A) the small-bore syringe 





2.7 Preclinical, Functional Model of Compatibility 
Animal Care and Use Statement:  Study protocols were approved by the University 
of Memphis IACUC protocol #0758.  All appropriate measures were taken to 
minimize pain and discomfort.  
Male Wistar rats were subject to a surgical procedure to create an orthopaedic 
defect superficial to the tibial tuberosity and expansion of a femoral muscular pouch in 
which experimental implants were inserted.  The study observed 5 groups: a positive 
control group of rats which receive the same orthopaedic defect but no implant (n=3), 
Control Sponge coupons (n=3, 24mg), Gelfoam® gelatin sponges (n=6, 24mg), PEG 
paste (n=6, 26mg), and the thermogel paste (n=6, 24mg).  Prior to implantation, 
implants are hydrated with sterile 1X PBS (200µl).    
The rat subjects were anesthetized using isoflurane inhalation.  Right hind limbs 
were shaved and cleaned with betadine; and a 1mm deep incision of approximately 
5mm in length were made superficially to the tibial tuberosity via a No. 10 scalpel 
blade, exposing the femoral epicondyle and proximal tibia head (Fig. 5A).  An 
abberation was made with the scalpel to increase the hard tissue surface area exposed 
to the implant and as an identification marker for later histological processing (Fig. 
5B).  Using surgical scissors, a muscular pouch was formed within the adductor 
muscular group in the medial lower thigh of the rats.  The chitosan sponge and 
Gelfoam® samples were then inserted via tweezers and the chitosan paste injected via 
a 1mL tuberculin syringe (Fig. 5C-D).  Two subcutaneous sutures sealed the muscular 
pouch and the incision closed with 2 staples.  The subjects were administered 
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subcutaneous injections (0.1mL) of Rimadyl 24hr and 48hr post-surgery for pain 
management.   
Rats were euthanized at 7 days via carbon monoxide asphyxiation, the right hind 
limbs excised and preserved in a 10% neutral formalin solution for a minimum of 14 days 
before histological processing.  The tissue samples were decalcified and embedded in 
paraffin.  Longitudinal sections were cut in the sagittal plane of the limb samples with an 
approximate thickness of 5µm, then stained with hematoxylin and eosin.  High resolution 
montages of the stained tissue sections, fixed to histology slides, were created via a 
Nikon inverted microscope Eclipse TE300 operated by BIOQUANT OSTEO16 imaging 
software (Fig. 5E).  Qualitative histological analysis of the montages was performed by 
blinded reviewers (n=9) evaluating the inflammation based on the Knodell histologic 
activity index [45] and modified by Parker et al. [46].  The inflammation score range 
from 0 to 5: minimal to no inflammation received a score of 0; 1 for the presence of very 
mild cellular aggregation; 2 represents a moderately elevated level of cellular aggregation 
immediately surrounding the implant; 3 for a wider, darker ring of cellular aggregation 
surrounding the implant; 4 for moderate to acute cellular aggregation in a thicker layer 
surrounding the implant; and 5 for severe cellular aggregation as well as fibrous tissue 





Figure 5 A-E: Wistar rats are implanted with experimental samples to observe the 
correlation between the implant formulation and the inflammatory response; A. a 1 cm 
incision exposes the anterior tibia head; B. a bone defect was applied; C. a control sponge 
coupon is inserted into the intramuscular pouch; D. paste samples are subcutaneously 
injected; E. After 7 days, the rats are sacrificed, limbs explanted, and tissue undergoes 




2.8 Preclinical, Infected, Functional Model of Antimicrobial Efficacy  
Animal Care and Use Statement:  Study protocols were approved by the University of 
Arkansas School of Medical Sciences IACUC protocol #3579.  All appropriate measures 
were taken to minimize pain and discomfort.   
Five experimental groups of murine subjects (n=5) were inoculated with a 
polymicrobial infection of S. aureus and P. aeruginosa.  The infected functional model is 
adapted from a protocol reported by Bernthal et al. [50] and has been implemented to 
assess the efficacy of antibiotic-loaded chitosan paste in a report by Beretta et al [33].  
The murine subjects received isoflurane inhalation anesthesia and Avertin (400-600 
mg/kg).  The left hind limb shaved and antiseptically cleaned with povidone iodine and 
70% ethanol.  An incision of approximately 5mL in length and 1mL in depth was made 
superficially to the patella, exposing the femoral epicondyle.  A 26-gauge needle was 
bored into the exposed femoral epicondyle, then further expanded with a 23-gauge needle 
(Fig. 6A).  The inoculation media consisted of 104 colonies of S. aureus (UAMS-1) and 
104 colonies of P. aeruginosa (ATCC 27317) suspended in 2 μl of phosphate buffered 
saline. Inoculum was injected into the newly formed intramedullary cavity. A stainless 
steel Kirshner wire (1cm) was then inserted into the intramedullary cavity (Fig. 6B-C).   
Subjects belonging to group 1, the negative control group, received no form of 
prophylaxis at all.  Group 2 was administered antibiotics systemically via an 
intraperitoneal injection of the antibiotic-loaded PBS (100µl) containing vancomycin 
(10mg/mL) and amikacin (10mg/mL) post-surgery.  The third experimental group was 
treated with neutral chitosan sponge coupons (diameter 8mm, 20mg) hydrated with the 
same antibiotic-loaded PBS (100µl) as the previous group, then inserted adjacent to the 
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orthopaedic implant at the distal base of the femur.  The thermogel experimental paste 
(24mg) and PEG paste (26mg) samples were hydrated (100µl) with the antibiotic-loaded 
PBS containing vancomycin (10mg/mL) and amikacin (10mg/mL)  then injected into 
the subcutaneous pouch surrounding the infected intramedullary implant (Fig. 6D).   
Following administration of each form of prophylaxis, the surgical site was sutured, 
and the mice were monitored for 7 days before being sacrificed via carbon monoxide 
asphyxiation.  The left hind limb is explanted, and the k-wires removed. The k-wires 
retrieved from each group were used to detect the presence of bacterial CFUs.  The k-
wires were sonicated in sterile PBS, serially diluted, and plated on TSB agar plates.  
The explanted thighs are removed of soft tissue, minced, homogenized, and diluted in 
a sterile saline solution, plated on a TSB agar plate.  The bacterial CFUs formed from 







Figure 6: (A) needle bored into murine femoral epicondyle; (B) insertion of k-wire into 
intramedullary cavity; (C) X-ray image of explanted limb illustrating implant location; 





2.9 Statistical Analysis  
For all applicable data, normality was determined via the Shapiro-Wilk test.  To 
detect significant differences in the data retrieved from the cytocompatibility and 
injectability studies, an ordinary one-way Analysis of Variance (ANOVA) followed 
by Holm-Sidak’s post-hoc analysis to detect differences among experimental groups.  
Data from the in vitro antibiotic elution and enzymatic degradation studies were 
analyzed via a two-way ANOVA followed by Holm-Sidak’s post-hoc analysis to 
identify significant differences with both time and experimental group as factors.  
Where applicable, all graphical results are presented as the average ± standard 
deviation. 
Data gathered from the in vivo models of functional compatibility and 
antimicrobial efficacy can be considered non-parametric and analyzed accordingly.  
The inflammation scores from the rat compatibility study, as well as the bacterial 
CFU counts and infection clearance rates from the infected orthopaedic study do not 
exhibit a Gaussian population distribution.  Statistical analysis is performed via the 
Kruskal-Wallis one-way analysis of variance test followed by Dunn’s multiple 
comparisons test to identify statistical differences among all experimental groups. A 




Results and Discussion 
3.1 Cytocompatibility 
The thermogel elicited a viability response not significantly different from the Control 
Sponge group (p<0.003), with average cell counts of approximately 1.0*105 and 1.3*105 
respectively.  However, the thermogel exhibited significantly lower cytocompatibility 
than the PEG Paste (p<0.003) and the Control Particulate samples (p<0.001) (Fig. 7).  
Although the thermogel elicited the lowest average cell count among all experimental 
groups, a cellular response similar to the Control Sponge group is a positive finding, as 
the cytocompatibility of chitosan has been well documented [51].  Ahmadi et al. reported 
on the cytotoxic response of fibroblast cells exposed to chitosan hydrogels composited 
with β-GP [35], concluding a chitosan hydrogel with a β-GP content of no more than 
10% (wt.) does not pose major cytotoxicity threats, allowing it to be used as a therapeutic 
delivery device.  It is possible that lowering the content of β-GP would improve the 
cytocompatibility of the thermogel experimental paste.   The favorable NIH3T3 viability 
response elicited by the PEG Paste, compared to the thermogel was expected; as the 
cytocompatibility benefits of adding PEG to chitosan have been well documented.  The 
presence of PEG has been shown to lessen the cytotoxicity of lyophilized chitosan 






Figure 7: Viability response of NIH3T3 cells after 72h of indirect exposure to the control 
and experimental chitosan samples (n=3); data is presented as the average cell count ± 
STD; * represents a significant difference against all groups (p≤0.0001); # represents a 






3.2 Antibiotic Elution and Activity  
Thermogel released both amikacin and vancomycin at infection-inhibiting levels for at 
least 72 hours in all evaluations of the in vitro model, including the antibiotics elution 
profiles (Fig. 8) and corresponding ZOI analysis of the eluate samples (Table 2.2). The 
pairing of the thermogel chitosan paste formulation and amikacin presents the most 
effective drug release profile, releasing at levels therapeutically effective against P. 
aeruginosa for 4 days.  Vancomycin is released from the thermogel device at levels 
comparable to the PEG Paste, detected for up to 5 days, and active against S. aureus 
through 72hr based on ZOI analysis.  
The thermogel chitosan paste samples released amikacin at concentrations 
significantly higher than the PEG Paste and Control Particulate groups on Day 1 
(p<0.019), and highest among all groups on Day 2 (p<0.05).  The thermogel group 
demonstrated the most prolonged antimicrobial efficacy against P. aeruginosa, through 
day 4.  With reported minimum inhibitory concentrations (MIC) of approximately 14 
µg/mL [59, 60], findings support the favorable amikacin elution profile.   
On Day 1, the Control Sponge group released vancomycin at a significantly higher 
concentration than all other chitosan paste groups (p<0.05).  There were no significant 
differences detected after Day 1, but thermogel displays an extended elution time 
comparable to the PEG Paste group.  The Control Particulate and PEG Paste eluates 
inhibit the growth of S. aureus through Day 4, the longest time of activity.  With a MIC 
of approximately 1-2µg/mL [61, 62], the thermogel eluate samples proved effective in 
inhibiting microbial growth through Day 3.  
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The elution profiles of both antibiotics illustrate an initial drug burst release from 
all experimental groups.  Initially, both amikacin and vancomycin were released from 
the Control Sponge group at higher concentrations than the thermogel.  As the study 
progressed the thermogel demonstrated a prolonged release of the antibiotics at 
therapeutic levels, while the Control Sponge purges all loaded antibiotics by Day 2.  
The in vitro elution profiles of vancomycin for the thermogel and PEG Paste are in 
agreement with those reported in studies of other chitosan drug delivery systems 
blended with composites.  A study by Berretta et al. [33] of chitosan pastes blended 
with a varying PEG content investigated the amikacin and vancomycin elution profiles 
of the scaffolds, concluding all chitosan paste blends eluted both antibiotics at 
therapeutic levels for at least 72 hours.  The antibiotic release profiles of the thermogel 
paste are comparabale to the favorable drug release characteristics studied in a report 
by Ruel-Gariepy et al. of temperature-sensitive drug delivery systems consisting of 
chitosan hydrogels composited with β-GP [63].  The authors note the chitosan drug 
delivery systems are capable of being loaded with a wide range of drugs, including 
antibiotics.  As amikacin is an aminoglycoside, electrostatic forces of attraction among 
the polyelectrolyte complex of chitosan and β-GP and the positively charged amine 
groups of amikacin could be a reason for the favorable pharmacokinetics of the 
pairing; similar to the electrostatic forces which bind the antibiotic to the ribosomal 







Figure 8: Concentrations of (A) vancomycin and (B) amikacin measured in eluate 
samples (n=3) gathered over a 7-day study, data is presented as the average concentration 
of the eluate solution ± STD.  * represents a concentration significantly higher than all 
other groups at the time point (p<0.05)   
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Table 2.1 Serial dilution of antibiotic concentrations as a standard for zone of inhibition 
analysis; green represents the presence of a zone of inhibition while red represents no 
antimicrobial efficacy.  
A.   Staphylococcus aureus Zone of Inhibition Diameter (mm) 
Antibiotic 
(µg/mL) 
10000 1000 100 10 1 
Vancomycin 9.4 7.1 3.6 1.7 0 
Amikacin 13.7 9.4 2.5 0.4 0 
Combination 12.4 7.4 3.5 0 0 
B.   Pseudomonas aeruginosa Zone of Inhibition Diameter (mm) 
Vancomycin 0 0 0 0 0 
Amikacin 19.8 12.4 5.1 0 0 
Combination 18.9 11.9 3.6 0 0 
 
Table 2.2 Zone of inhibition diameters formed from eluate samples from elution study. 
A.   Staphylococcus aureus Zone of Inhibition Diameter (mm) 
Group 
Antibiotic Eluate Time Point (day) 
1 2 3 4 5 6 7 
1. Control Sponge 11.6 7.1 2.9 0 0 0 0 
2. Control Particulate 12.5 7.7 6.2 2.6 0 0 0 
3. Thermogel 10.9 6.8 4.2 0 0 0 0 
4. PEG paste 8.9 7.9 5.6 1.9 0 0 0 
B.   Pseudomonas aeruginosa Zone of Inhibition Diameter (mm) 
1. Control Sponge 12.7 8.2 0 0 0 0 0 
2. Control Particulate 12.4 9.7 2.5 0 0 0 0 
3. Thermogel 12.1 9.6 2.8 1.5 0 0 0 






The thermogel and PEG Paste groups demonstrated a significantly higher degradation 
rate than the Control Sponge and Particulate groups based on the percentage of initial 
mass remaining at every sample time point (p<0.0001).  Just after 24 hours, the 
thermogel and PEG paste samples were reduced to approximately 55% and 60% of the 
initial mass respectively.   There were no significant differences in the rate of enzymatic 
degradation among the PEG Paste and thermogel groups at any time point during the 
study (Fig. 9).  The Control Sponge and Particulate groups displayed a minimal mass-
based reduction over the 7-day study; retaining approximately 100% to 75% of the 
original mass, respectively.  There was no significant difference in percentage of initial 
mass remaining among the control groups on days 1, 3, and 5.  However, on Day 7 the 
percentage of initial mass remaining of the Control Particulate was significantly lower 
compared to the Control Sponge (p<0.002).   
The notable difference in degradation among the Control Sponge and Control 
Particulate Groups on Day 7 can be attributed to the increased surface area of the 
Chitosan Paste group.  As chitosan scaffolds swell in aqueous solutions, enzymes can be 
restricted from freely transporting into the matrix; causing surface erosion to be the 
primary degradation mechanism in smaller chitosan implants. The differences in 
degradation support the claim that the degradation rate of lyophilized chitosan is 
proportional to its surface area [56, 57].   
The acidic chitosan in the experimental paste formulations can be a factor increasing 
hydrolytic degradation.  The protonated amine group of acidic chitosan dissociates from 
the chitosan molecule in aqueous solutions; facilitating the solubilization of the chitosan 
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molecules [21].  Rhodes et al. studied the in vitro degradation of chitosan-PEG 
blended pastes formulated in varying ratios of acidic to neutral chitosan.  It was noted 
the degradation rate increased with an increased acidity of the chitosan paste 
formulation [34].  The paste groups were degraded to approximately 10-30% of their 
initial mass after 6 days, comparable value to the chitosan paste groups in the current 
study where the thermogel degraded to approximately 40% of the initial mass after 7 
days of lysozyme-based degradation. 
An increased surface area may also contribute to the chitosan paste degradation as 
well.  Additionally, composite materials in blends may also contribute to degradation.  
Composite chitosan scaffolds created from a physical blend, such as the PEG Paste, or 
a weak polyelectrolyte complex such as the thermogel, are more susceptible to 
hydrolytic degradation than chitosan-only constructs, promoting the overall rate of 
degradation of the construct [65, 66].  The addition of PEG causing an increased 
degradation rate in chitosan constructs has been demonstrated previously in a study by 





Figure 9: Enzymatic degradation of experimental chitosan samples (n=3) over the 7-day 
study, data is presented as the average percent of the initial mass ± STD;  * represents a 
significant difference in percent of initial mass remaining compared to both the Control 
Sponge and Particulate groups (p<0.0001);  # represents a significant difference in 








For both variations of syringe bore diameter, the thermogel exhibited a reactant 
force of ejection comparable to the PEG Paste, and well below the average measured 
force of ejection exerted by volunteers on the syringe modified with a load cell.  For 
both the thermogel and PEG paste, the small-bore syringe (diameter 2mm) required a 
significantly higher ejection force than the large-bore syringe (diameter 7mm) 
(p<0.002).  It is worth noting the thermogel displayed a consistency with a very low 
viscosity and the test was performed at room temperature (20°C). 
Findings are in agreement with previous research into the injectability of chitosan 
paste, such as the ejection forces reported in a study by Berretta et al. of chitosan 
pastes blended with PEG being ejected from a large-bore syringe [33].  In the study, 
the PEG Paste was tested alongside another chitosan paste which had a 1:1 mass ratio 
of neutral chitosan to acidic chitosan composite, similar to the thermogel formulation 
in the current study.  A potential benefit of adding β-GP to the chitosan paste 
formulation is improved injectability, due to the low viscosity of the paste at room 
temperature (20°C).  The authors of a study of thermo-responsive drug delivery 
systems noted the chitosan/β-GP mixtures displayed a liquid-like behavior at low 




Figure 10: Injectability of the experimental paste samples (n=3) from syringes with tips 
of large diameter (LD) and a small diameter (SD), compared to a benchmark value for a 
comfortable force of ejection; data is represented as the average ejection force ± STD; * 





3.5 Preclinical, Functional Model of Compatibility  
Based on the results of qualitative histological analysis of the degree of 
inflammation, the PEG paste elicited the highest inflammatory response among all 
experimental groups.  The PEG paste (p<0.0001) and thermogel (p<0.027) provoked 
an inflammatory response significantly more severe than the Control Sponge, the 
Gelfoam® gelatin sponge, and the No Implant control groups.  There is no statistical 
difference between experimental groups (p<0.073), although the PEG Paste scored a 
slightly higher average inflammation level than the thermogel, with scores of 
approximately 3.5 and 2.9 respectively.  Compared to the subjects which did not 
receive implants, there was no statistical difference in the level of inflammation 
elicited by the Control Sponge samples, or the Gelfoam® gelatin sponge (p≥0.08) 
(Fig. 11).  
The inflammation elicited by the Control Sponge was not significantly different 
from the Gelfoam® and No Implant groups.  As a naturally-derived polymer, chitosan 
provokes a minimal foreign body response.  A characteristic which is supported by the 
results of the current study and many more publications reviewing studies of the 
foreign body response to chitosan implants [58, 69, 70].  One example is a study by 
VandeVord et al., in which authors investigate the foreign body reaction to lyophilized 
chitosan sponges implanted subcutaneously into murine host subjects for up to 12 
weeks.  No pathological inflammation in response to the chitosan was detected for the 
duration of the study [71].   
The increased level of inflammation caused by the thermogel and PEG paste is 
potentially a result of the dissolution of the acidic chitosan components, decreasing the 
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pH of the tissue and bodily fluids immediately surrounding the implant.  Also, an 
increased surface area may attract activated macrophages which secrete reactive 
oxygen species capable of causing local acidosis [72, 73].  It has been noted that as the 
microenvironment surrounding an implant becomes more acidic the inflammatory 
response to the implant is more severe, and acidic chitosan will degrade at an increased 
rate [74-76].  The thermogel may provoke a lower inflammatory response than the PEG 
Paste due to the presence of the neutral chitosan, as well as the basic β-GP additive which 
can potentially buffer acidosis [68].  The inflammation scores of the thermogel and PEG 
paste groups are comparable to the results from similar studies of in vivo compatibility of 
chitosan blended with PEG in lyophilized sponge form by Parker et al. [129], as well as 
in a paste form by Rhodes et al. [1].  In both sponge and paste form, the acidic chitosan 
modified with composites produced more inflammatory response than the control neutral 





Figure 11: Histologic analysis results presented as a 5-95 percentile box and whisker plot 
of the average inflammation score with the mean represented as (+); the inflammation 
score ranges from 0 to 5: minimal to no inflammation receives a score of 0; a 1 for the 
presence of very mild cellular aggregation; a 2 represents a moderately elevated level of 
cellular aggregation immediately surrounding the implant; a 3 for a wider, darker ring of 
cellular aggregation surrounding the implant; a 4 for moderate to acute cellular 
aggregation in a thicker layer surrounding the implant; and a 5 for obvious, severe 
cellular aggregation as well as fibrous tissue formation encapsulating the implant.  * 
represents a significant difference from the No Implant, Control Sponge, and Gelfoam® 




3.6 Preclinical, Infected, Functional Model of Antimicrobial Efficacy 
Although no statistical significances were noted among the groups in both the CFU 
count (Fig. 12) and the clearance percentage (Fig. 13), the data gathered from the present 
study can provide insight into the efficacy of the experimental thermogel chitosan paste.  
Additionally, it can provide valuable evidence about various mechanisms of infection 
prevention.  S. aureus is known to spread to the surrounding hard and soft tissue much 
more so than P. aeruginosa as well as colonizing onto the implant.  The systemic 
administration of the antibiotics had the lowest average count of S. aureus CFUs for both 
the k-wires and surrounding hard tissue.  The average count of S. aureus CFUs harvested 
from the k-wires ranges between 103 and 104 CFUs, with the systemic antibiotics group 
averaging 723 CFUs.  The systemic antibiotic administration cleared 75% of k-wires of 
S. aureus.  Both the thermogel and PEG Paste eradicated all S. aureus microbials in 25% 
of k-wires. However, all methods of prophylaxis allowed some proliferation and 
migration of S. aureus to the surrounding tissues.   
With an average P. aeruginosa CFU count of 10 per k-wire, the thermogel produced 
comparable CFU counts to the Systemic Antibiotics group at 7.5 CFUs and the PEG 
Paste at 2 CFUs relative to the high CFU counts of the other experimental groups.  The 
subjects administered antibiotics via the thermogel and PEG Paste delivery systems 
effectively prevented the colonization of P. aeruginosa on 75% of implanted k-wires, 
while administration of antibiotics systemically cleared infection in 50% of explanted k-
wires.  The subjects treated with the Control Sponge formed an average of 88 CFUs per 
k-wire and did not clear infection in any of the implanted pins and was not lower than the 
negative control group.   
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As for the results gathered from the femoral hard tissue, the thermogel delivery 
device most effectively inhibited the growth of P. aeruginosa with the lowest average 
CFU count, 72.5 CFUs per samples, and highest clearance ability, 50% of samples. 
The PEG paste group did present the highest average CFU count in the surrounding 
tissue among all groups, with approximately 1000 CFUs per sample.  It is possible the 
thermogel group conforms to the wound prior to the thermo-responsive gelation; as 
opposed to the more viscous consistency of the PEG paste.   
While the subject size of the experiment is limited, cross-referencing applicable 
data such as the results of the in vivo antimicrobial study and the in vitro antibiotic 
elution study can help lead to conclusions.  Based on CFU counts alone, all methods 
of prophylaxis proved ineffective in preventing the bacterial adherence, colonization, 
and formation of biofilm.  The aggressive invasion, colonization, and biofilm 
formation of S. aureus is not surprising, as Staphylococcal bacterial species have been 
reported as the most commonly isolated microbial organisms from orthopaedic 
implants and devices [77], capable of efficient biofilm formation [78], with a rapid 
growth in bone tissue [79].  It has also has been noted that glycopeptide antibiotics, 
such as vancomycin, do not effectively penetrate tissue, an explanation for the poor 
antimicrobial efficacy in the femoral tissue samples surrounding the implant [80].  
Many observations can be made from the results of the P. aeruginosa CFU counts.  
For example, one could imply the P. aeruginosa organism does not thrive in this 
murine orthopaedic model as well as the S. aureus bacterial species did.  The 
thermogel appears to be the most effective antibiotic delivery system in preventing the 
colonization of P. aeruginosa as well as effectively eliminating the presence of the 
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bacteria altogether.  A cross-reference of the results of the antibiotic elution profile, ZOI 
analysis, and the in vivo antimicrobial study supports the previous conclusion.  
Intermolecular interactions between the aminoglycoside antibiotic and the polyelectrolyte 
complex originating between the polycationic chitosan backbone and the β-GP additive 
could enhance the efficacy of drug delivery vehicle.  Just as electrostatic forces allow 
aminoglycosides to bind to the RNA complexes within a microbial organism, there could 




Figure 12: Box and whisker plot of the average number of Colony Forming Units (CFUs) 
of the re retrieved from the (A) explanted Kirshner wires and (B) homogenates of 
surrounding femoral hard tissue; the mean is represented as a (+) with a box and whisker 




Figure 13: Infection-clearance ability of prophylactic methods, represented as the 
percentage of (A) k-wires and (B) hard tissue samples cleared of infection, meaning the 




The functional and clinical efficacy of the thermogel are evaluated within the 
scope of musculoskeletal wounds resultant of high energy trauma at risk of infection.  
Findings reveal thermogel is an injectable and degradable biomaterial capable of 
point-of-care antibiotic loading, and local, therapeutic antibiotic release.  There is 
room for improvement in the cytocompatibility of the thermogel, yet a cellular 
viability response similar to the cytocompatible Control Sponge group is a positive 
sign.  In vitro studies reveal the thermogel chitosan paste is more susceptible to 
enzymatic degradation than the Control Sponge and Particulate.  The antibiotic 
elution profiles and activity of the thermogel experimental group demonstrate a more 
efficient mechanism of drug release compared to the chitosan Control groups; with an 
apparent affinity for amikacin over vancomycin, potentially due to intermolecular 
interactions.  The thermogel displayed favorable injectability prior to the thermo-
responsive gelation; with forces of ejection comparable to the PEG paste benchmark 
group.  Preclinical studies of functional compatibility and antimicrobial efficacy 
demonstrate the thermogel is capable of treating an established bacterial 
contamination and eliciting a minimal foreign body reaction.  The inflammatory 
response provoked by the thermogel is less severe than the PEG Paste and more 
severe than the control groups.  The animal subjects receiving the implants did not 
demonstrate any signs of discomfort or pain caused by the thermogel.  The preclinical 
study of antimicrobial efficacy indicates thermogel as an effective infection 
prevention tool in an infected, complex musculoskeletal wound.   
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The formulation of the thermogel should be further researched with hopes of 
modifications or additives capable of extending antibiotic elution time and efficacy, 
as well as improving the cytotoxic response and in vivo biocompatibility.  Potential 
modifications to the thermogel may be a lower β-GP content which could improve the 
cytocompatibility.  Additionally, a higher ratio of neutral chitosan particulate to acidic 
chitosan in the formulation could result in both improved compatibility and drug release 
characteristics.  Improvements could be made to the grinding process of the lyophilized 
chitosan sponges in order to achieve more uniform flake size which can be measured.  
Also, a more finely ground particulate could help create a more homogenous paste.  If the 
in vivo compatibility of the paste can be improved, then future work will further evaluate 
the thermogel drug delivery system in an expanded preclinical model of complex, 




Research reported in this publication is supported by the National Institute of 
Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health 
under Award Number R01AR066050.  The content is solely the responsibility of the 
author and does not necessarily represent the official views of the National Institutes 
of Health.  The authors would like to thank Mike Harris for his assistance with HPLC 
methods among other contributions, as well as the guidance of Dr.’s Warren O. 





[1] C.K. Lee, S.L. Hansen, Management of acute wounds, Surgical Clinics of North 
America 89(3) (2009) 659-676. 
[2] M. Richardson, Acute wounds: an overview of the physiological healing process, 
Nursing times 100(4) (2003) 50-53. 
[3] W.T. Lawrence, Physiology of the acute wound, Clinics in plastic surgery 25(3) 
(1998) 321-340. 
[4] R.F. Edlich, General requirements for controlled clinical trials of antibiotic treatment 
of soft tissue lacerations, Annals of emergency medicine 18(8) (1989) 900. 
[5] H. Park, C. Copeland, S. Henry, A. Barbul, Complex wounds and their management, 
The Surgical clinics of North America 90(6) (2010) 1181-94. 
[6] E.G. Krug, G.K. Sharma, R. Lozano, The global burden of injuries, Am J Public 
Health 90(4) (2000) 523-6. 
[7] W.H. Organization, Cause-specific mortality: regional estimates for 2008, Geneva: 
WHO  (2011). 
[8] F.P. Rivara, C. Mock, The 1,000,000 lives campaign, Inj Prev 11(6) (2005) 321-3. 
[9] H.B. Skinner, Current diagnosis & treatment in orthopedics, 2006. 
[10] J.L. Esterhai, A.G. Gristina, R. Poss, Musculoskeletal infection, American Academy 
of Orthopaedic Surgeons, Park Ridge, IL, 1992. 
[11] G.B. Andersson, J. Bouchard, B. KJ, The burden of musculoskeletal diseases in the 
United States : prevalence, societal and economic cost, American Academy of 
Orthopaedic Surgeons, Rosemont, IL, 2008. 
[12] C.G. Zalavras, M.J. Patzakis, P.D. Holtom, R. Sherman, Management of open 
fractures, Infectious Disease Clinics of North America 19(4) (2005) 915-29. 
[13] H. Carsenti-Etesse, J. Entenza, J. Durant, C. Pradier, V. Mondain, E. Bernard, P. 
Dellamonica, Efficacy of subinhibitory concentration of pefloxacin in preventing 
experimental Staphylococcus aureus foreign body infection in mice, Drugs under 
experimental and clinical research 18(10) (1991) 415-422. 
[14] N. Høiby, O. Ciofu, H.K. Johansen, Z.-j. Song, C. Moser, P.Ø. Jensen, S. Molin, M. 
Givskov, T. Tolker-Nielsen, T. Bjarnsholt, The clinical impact of bacterial biofilms, 
International journal of oral science 3(2) (2011) 55. 
[15] E.F. Berbari, A.D. Hanssen, M.C. Duffy, J.M. Steckelberg, D.M. Ilstrup, W.S. 
Harmsen, D.R. Osmon, Risk factors for prosthetic joint infection: case-control study, 
Clinical Infectious Diseases 27(5) (1998) 1247-1254. 
[16] W.V. Arnold, M.E. Shirtliff, P. Stoodley, Bacterial biofilms and periprosthetic 
infections, J Bone Joint Surg Am 95(24) (2013) 2223-2229. 
[17] J.W. Costerton, Z. Lewandowski, D.E. Caldwell, D.R. Korber, H.M. Lappin-Scott, 
Microbial biofilms, Annual Reviews in Microbiology 49(1) (1995) 711-745. 
77 
 
[18] J.B. Eckman Jr, S.L. Henry, P.D. Mangino, D. Seligson, Wound and serum levels of 
tobramycin with the prophylactic use of tobramycin-impregnated 
polymethylmethacrylate beads in compound fractures, Clin Orthop Relat Res 237 (1988) 
213-215. 
[19] M. Diefenbeck, T. Mückley, G.O. Hofmann, Prophylaxis and treatment of implant-
related infections by local application of antibiotics, Injury 37(2, Supplement) (2006) 
S95-104. 
[20] A.D. Hanssen, Local antibiotic delivery vehicles in the treatment of musculoskeletal 
infection, Clin Orthop Relat Res (437) (2005) 91-6. 
[21] M. Rinaudo, Chitin and chitosan: Properties and applications, Progress in Polymer 
Science 31(7) (2006) 603-632. 
[22] S.A. Agnihotri, N.N. Mallikarjuna, T.M. Aminabhavi, Recent advances on chitosan-
based micro- and nanoparticles in drug delivery, J Control Release 100(1) (2004) 5-28. 
[23] S. Danielsen, S. Strand, C. de Lange Davies, B.T. Stokke, Glycosaminoglycan 
destabilization of DNA-chitosan polyplexes for gene delivery depends on chitosan chain 
length and GAG properties, Biochim Biophys Acta 1721(1-3) (2005) 44-54. 
[24] A. Di Martino, M. Sittinger, M.V. Risbud, Chitosan: a versatile biopolymer for 
orthopaedic tissue-engineering, Biomaterials 26(30) (2005) 5983-90. 
[25] M. Ishihara, K. Nakanishi, K. Ono, M. Sato, M. Kikuchi, Y. Saito, H. Yura, T. 
Matsui, H. Hattori, M. Uenoyama, Photocrosslinkable chitosan as a dressing for wound 
occlusion and accelerator in healing process, Biomaterials 23(3) (2002) 833-840. 
[26] P.J. VandeVord, H.W. Matthew, S.P. DeSilva, L. Mayton, B. Wu, P.H. Wooley, 
Evaluation of the biocompatibility of a chitosan scaffold in mice, J Biomed Mater Res 
59(3) (2002) 585-90. 
[27] M. Dash, F. Chiellini, R.M. Ottenbrite, E. Chiellini, Chitosan—A versatile semi-
synthetic polymer in biomedical applications, Progress in Polymer Science 36(8) (2011) 
981-1014. 
[28] S.P. Noel, H.S. Courtney, J.D. Bumgardner, W.O. Haggard, Chitosan sponges to 
locally deliver amikacin and vancomycin: a pilot in vitro evaluation, Clin Orthop Relat 
Res 468(8) (2010) 2074-80. 
[29] E. Vunain, A. Mishra, B. Mamba, Fundamentals of chitosan for biomedical 
applications, Chitosan Based Biomaterials Volume 1: Fundamentals  (2016) 1. 
[30] A.C. Parker, K.E. Beenken, J.A. Jennings, L. Hittle, M.E. Shirtliff, J.D. 
Bumgardner, M.S. Smeltzer, W.O. Haggard, Characterization of local delivery with 
amphotericin B and vancomycin from modified chitosan sponges and functional biofilm 
prevention evaluation, Journal of Orthopaedic Research  (2014). 
[31] D.J. Stinner, S.P. Noel, W.O. Haggard, J.T. Watson, J.C. Wenke, Local antibiotic 
delivery using tailorable chitosan sponges: the future of infection control?, Journal of 
orthopaedic trauma 24(9) (2010) 592-7. 
78 
 
[32] L.C. Jones, C. Frondoza, D.S. Hungerford, Effect of PMMA particles and movement 
on an implant interface in a canine model, J Bone Joint Surg Br 83(3) (2001) 448-58. 
[33] J.M. Berretta, J.A. Jennings, H.S. Courtney, K.E. Beenken, M.S. Smeltzer, W.O. 
Haggard, Blended Chitosan Paste for Infection Prevention: Preliminary and Preclinical 
Evaluations, Clinical Orthopaedics and Related Research®  (2017) 1-14. 
[34] C.S. Rhodes, C.M. Alexander, J.M. Berretta, H.S. Courtney, K.E. Beenken, M.S. 
Smeltzer, J.D. Bumgardner, W.O. Haggard, J.A. Jennings, Evaluation of a chitosan-
polyethylene glycol paste as a local antibiotic delivery device, World Journal of 
Orthopedics 8(2) (2017) 130. 
[35] R. Ahmadi, J.D. de Bruijn, Biocompatibility and gelation of chitosan–glycerol 
phosphate hydrogels, Journal of Biomedical Materials Research Part A 86(3) (2008) 824-
832. 
[36] A.C. Parker, C.S. Rhodes, J.A. Jennings, L. Hittle, M. Shirtliff, J.D. Bumgardner, 
W.O. Haggard, Preliminary Evaluation of Local Drug Delivery of Amphotericin B and In 
Vivo Degradation of Chitosan and Polyethylene Glycol Blended Sponges, Journal of 
Biomedical Materials Research Part B: Applied Biomaterials 104(1) (2016) 78-87. 
[37] M.M.D.C. Vila, R.M. de Oliveira, M.M. Goncalves, M. Tubino, Analytical methods 
for vancomycin determination in biological fluids and in pharmaceuticals, Quim Nova 
30(2) (2007) 395-399. 
[38] J.B. McClain, R. Bongiovanni, S. Brown, Vancomycin quantitation by high-
performance liquid chromatography in human serum, J Chromatogr 231(2) (1982) 463-6. 
[39] A.P. Sattur, J.-H. Lee, K.-B. Song, T. Panda, C.-H. Kim, S.-K. Rhee, B. Gokul, 
Analytical techniques for vancomycin—A review, Biotechnology and Bioprocess 
Engineering 5(3) (2000) 153-158. 
[40] M.A. Omar, H.M. Ahmed, M.A. Hammad, S.M. Derayea, Validated 
spectrofluorimetric method for determination of selected aminoglycosides, 
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 135 (2015) 472-8. 
[41] H. Ericsson, G. Tunevall, K. Wickman, The paper disc method for determination of 
bacterial sensitivity to antibiotics. Relationship between the diameter of the zone of 
inhibition and the minimum inhibitory concentration, Scandinavian journal of clinical 
and laboratory investigation 12(4) (1960) 414-22. 
[42] J.W. Costerton, Z. Lewandowski, D.E. Caldwell, D.R. Korber, H.M. Lappin-Scott, 
Microbial biofilms, Annual review of microbiology 49 (1995) 711-45. 
[43] K.M. Varum, M.M. Myhr, R.J. Hjerde, O. Smidsrod, In vitro degradation rates of 
partially N-acetylated chitosans in human serum, Carbohydr Res 299(1-2) (1997) 99-101. 
[44] A.H. Fischer, K.A. Jacobson, J. Rose, R. Zeller, Hematoxylin and eosin staining of 
tissue and cell sections, Cold Spring Harbor Protocols 2008(5) (2008) pdb. prot4986. 
[45] V.J. Desmet, Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, 
Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for 
assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 
1981; 1: 431–435], Journal of hepatology 38(4) (2003) 382-386. 
79 
 
[46] A.C. Parker, J.A. Jennings, J.D. Bumgardner, H.S. Courtney, E. Lindner, W.O. 
Haggard, Preliminary investigation of crosslinked chitosan sponges for tailorable drug 
delivery and infection control, J Biomed Mater Res B Appl Biomater 101(1) (2013) 110-
23. 
[47] K.E. Beenken, P.M. Dunman, F. McAleese, D. Macapagal, E. Murphy, S.J. Projan, 
J.S. Blevins, M.S. Smeltzer, Global gene expression in Staphylococcus aureus biofilms, J 
Bacteriol 186(14) (2004) 4665-4684. 
[48] J.S. Rom, D.N. Atwood, K.E. Beenken, D.G. Meeker, A.J. Loughran, H.J. Spencer, 
T.L. Lantz, M.S. Smeltzer, Impact of Staphylococcus aureus regulatory mutations that 
modulate biofilm formation in the USA300 strain LAC on virulence in a murine 
bacteremia model, Virulence  (2017) 1-15. 
[49] M.S. Smeltzer, J.R. Thomas, S.G. Hickraon, R.A. Skinner, C.L. Nelson, D. Griffith, 
T.R. Parr, R.P. Evans, Characterization of a rabbit model of staphylococcal osteomyelitis, 
Journal of orthopaedic research 15(3) (1997) 414-421. 
[50] N.M. Bernthal, A.I. Stavrakis, F. Billi, J.S. Cho, T.J. Kremen, S.I. Simon, A.L. 
Cheung, G.A. Finerman, J.R. Lieberman, J.S. Adams, A mouse model of post-
arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of 
antimicrobial implant coatings, PloS one 5(9) (2010) e12580. 
[51] M. Dash, F. Chiellini, R. Ottenbrite, E. Chiellini, Chitosan—A versatile semi-
synthetic polymer in biomedical applications, Progress in Polymer Science 36(8) (2011) 
981-1014. 
[52] J. Wu, W. Wei, L.-Y. Wang, Z.-G. Su, G.-H. Ma, A thermosensitive hydrogel based 
on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system, 
Biomaterials 28(13) (2007) 2220-2232. 
[53] G. Jiang, J. Sun, F. Ding, PEG-g-chitosan thermosensitive hydrogel for implant drug 
delivery: cytotoxicity, in vivo degradation and drug release, J Biomater Sci Polym Ed 
25(3) (2014) 241-56. 
[54] C.T. Tsao, M.H. Hsiao, M.Y. Zhang, S.L. Levengood, M. Zhang, Chitosan-PEG 
hydrogel with sol-gel transition triggerable by multiple external stimuli, Macromolecular 
rapid communications 36(3) (2015) 332-8. 
[55] I.-Y. Kim, S.-J. Seo, H.-S. Moon, M.-K. Yoo, I.-Y. Park, B.-C. Kim, C.-S. Cho, 
Chitosan and its derivatives for tissue engineering applications, Biotechnology advances 
26(1) (2008) 1-21. 
[56] H.-Y. Cheung, K.-T. Lau, T.-P. Lu, D. Hui, A critical review on polymer-based bio-
engineered materials for scaffold development, Composites Part B: Engineering 38(3) 
(2007) 291-300. 
[57] C.M. Agrawal, R.B. Ray, Biodegradable polymeric scaffolds for musculoskeletal 
tissue engineering, Journal of Biomedical Materials Research 55(2) (2001) 141-50. 
[58] M. Swetha, K. Sahithi, A. Moorthi, N. Srinivasan, K. Ramasamy, N. Selvamurugan, 
Biocomposites containing natural polymers and hydroxyapatite for bone tissue 
engineering, International journal of biological macromolecules 47(1) (2010) 1-4. 
80 
 
[59] H. Giamarellou, N.P. Zissis, G. Tagari, J. Bouzos, In vitro synergistic activities of 
aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa, 
Antimicrob Agents Chemother 25(4) (1984) 534-536. 
[60] A. Nakamura, M. Hosoda, T. Kato, Y. Yamada, M. Itoh, K. Kanazawa, H. Nouda, 
Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in 
vitro, The Journal of antimicrobial chemotherapy 46(6) (2000) 901-4. 
[61] S.K. Fridkin, J. Hageman, L.K. McDougal, J. Mohammed, W.R. Jarvis, T.M. Perl, 
F.C. Tenover, V.-I.S.a.E.S. Group, Epidemiological and microbiological characterization 
of infections caused by Staphylococcus aureus with reduced susceptibility to 
vancomycin, United States, 1997–2001, Clinical Infectious Diseases 36(4) (2003) 429-
439. 
[62] S.J. van Hal, T.P. Lodise, D.L. Paterson, The clinical significance of vancomycin 
minimum inhibitory concentration in Staphylococcus aureus infections: a systematic 
review and meta-analysis, Clin Infect Dis 54(6) (2012) 755-71. 
[63] E. Ruel-Gariepy, A. Chenite, C. Chaput, S. Guirguis, J.-C. Leroux, Characterization 
of thermosensitive chitosan gels for the sustained delivery of drugs, International Journal 
of Pharmaceutics 203(1) (2000) 89-98. 
[64] L.K. Pickering, P. Gearhart, Effect of time and concentration upon interaction 
between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin, 
Antimicrob Agents Chemother 15(4) (1979) 592-596. 
[65] M.V. Zugravu, R.A. Smith, B.T. Reves, J.A. Jennings, J.O. Cooper, W.O. Haggard, 
J.D. Bumgardner, Physical properties and in vitro evaluation of collagen-chitosan-
calcium phosphate microparticle-based scaffolds for bone tissue regeneration, J Biomater 
Appl 28(4) (2013) 566-79. 
[66] G. Gorczyca, R. Tylingo, P. Szweda, E. Augustin, M. Sadowska, S. Milewski, 
Preparation and characterization of genipin cross-linked porous chitosan-collagen-gelatin 
scaffolds using chitosan-CO2 solution, Carbohydr Polym 102 (2014) 901-11. 
[67] A.C. Parker, C. Rhodes, J.A. Jennings, L. Hittle, M. Shirtliff, J.D. Bumgardner, 
W.O. Haggard, Preliminary evaluation of local drug delivery of amphotericin B and in 
vivo degradation of chitosan and polyethylene glycol blended sponges, J Biomed Mater 
Res B Appl Biomater 104(1) (2016) 78-87. 
[68] J. Cho, M.-C. Heuzey, A. Bégin, P.J. Carreau, Physical gelation of chitosan in the 
presence of β-glycerophosphate: the effect of temperature, Biomacromolecules 6(6) 
(2005) 3267-3275. 
[69] E.-R.S. Kenawy, M.M. Azaam, K.M. Saad-Allah, Synthesis and antimicrobial 
activity of α-aminophosphonates containing chitosan moiety, Arabian Journal of 
Chemistry 8(3) (2015) 427-432. 
[70] M.N. Kumar, R.A. Muzzarelli, C. Muzzarelli, H. Sashiwa, A.J. Domb, Chitosan 
chemistry and pharmaceutical perspectives, Chem Rev 104(12) (2004) 6017-84. 
81 
 
[71] P.J. VandeVord, H.W. Matthew, S.P. DeSilva, L. Mayton, B. Wu, P.H. Wooley, 
Evaluation of the biocompatibility of a chitosan scaffold in mice, Journal of Biomedical 
Materials Research Part A 59(3) (2002) 585-590. 
[72] J. Lassus, J. Salo, W.A. Jiranek, S. Santavirta, J. Nevalainen, M. Matucci-Cerinic, P. 
Horák, Y. Konttinen, Macrophage activation results in bone resorption, Clin Orthop Relat 
Res 352 (1998) 7-15. 
[73] A.S. Haka, I. Grosheva, E. Chiang, A.R. Buxbaum, B.A. Baird, L.M. Pierini, F.R. 
Maxfield, Macrophages create an acidic extracellular hydrolytic compartment to digest 
aggregated lipoproteins, Mol Biol Cell 20(23) (2009) 4932-40. 
[74] M.I. Oliveira, S.G. Santos, M.J. Oliveira, A.L. Torres, M.A. Barbosa, Chitosan 
drives anti-inflammatory macrophage polarisation and pro-inflammatory dendritic cell 
stimulation, Eur Cell Mater 24 (2012) 136-52; discussion 152-3. 
[75] J. Guzman-Morales, M.B. Ariganello, I. Hammami, M. Thibault, M. Jolicoeur, C.D. 
Hoemann, Biodegradable chitosan particles induce chemokine release and negligible 
arginase-1 activity compared to IL-4 in murine bone marrow-derived macrophages, 
Biochem Bioph Res Co 405(4) (2011) 538-44. 
[76] D. Fong, M.B. Ariganello, J. Girard-Lauziere, C.D. Hoemann, Biodegradable 
chitosan microparticles induce delayed STAT-1 activation and lead to distinct cytokine 
responses in differentially polarized human macrophages in vitro, Acta Biomaterialia 12 
(2015) 183-94. 
[77] J. Bernstein, Musculoskeletal medicine, Amer Academy of Orthopaedic2003. 
[78] C. Fux, J. Costerton, P. Stewart, P. Stoodley, Survival strategies of infectious 
biofilms, Trends in microbiology 13(1) (2005) 34-40. 
[79] A. Widaa, T. Claro, T.J. Foster, F.J. O’Brien, S.W. Kerrigan, Staphylococcus aureus 
protein A plays a critical role in mediating bone destruction and bone loss in 
osteomyelitis, PloS one 7(7) (2012) e40586. 
[80] P.E. Reynolds, Structure, biochemistry and mechanism of action of glycopeptide 
antibiotics, European Journal of Clinical Microbiology and Infectious Diseases 8(11) 
(1989) 943-950. 
[81] H. Wang, M. Roman, Formation and properties of chitosan-cellulose nanocrystal 
polyelectrolyte-macroion complexes for drug delivery applications, Biomacromolecules 
12(5) (2011) 1585-93. 
[82] J. Kondo, B. François, R.J. Russell, J.B. Murray, E. Westhof, Crystal structure of the 
bacterial ribosomal decoding site complexed with amikacin containing the γ-amino-α-
hydroxybutyryl (haba) group, Biochimie 88(8) (2006) 1027-1031. 
[83] T.A. Decoster, S. Bozorgnia, Antibiotic beads, J Am Acad Orthop Surg 16(11) 
(2008) 674-8. 
[84] M. Diefenbeck, T. Muckley, G.O. Hofmann, Prophylaxis and treatment of implant-
related infections by local application of antibiotics, Injury 37 Suppl 2 (2006) S95-104. 
82 
 
[85] R. Thonse, J. Conway, Antibiotic cement-coated interlocking nail for the treatment 
of infected nonunions and segmental bone defects, Journal of orthopaedic trauma 21(4) 
(2007) 258-268. 
[86] M. McKee, E.H. Schemitsch, L. Wild, J.P. Waddell, † The use of an antibiotic-
impregnated, bioahsorbable bone substitute in the treatment of infected long bone 
defects: Results of a prospective trial, Journal of orthopaedic trauma 14(2) (2000) 137-
138. 
[87] S.J. McConoughey, R.P. Howlin, J. Wiseman, P. Stoodley, J.H. Calhoun, 
Comparing PMMA and calcium sulfate as carriers for the local delivery of antibiotics to 
infected surgical sites, Journal of Biomedical Materials Research Part B: Applied 
Biomaterials 103(4) (2015) 870-877. 
[88] N.D. Webb, J.D. McCanless, H.S. Courtney, J.D. Bumgardner, W.O. Haggard, 
Daptomycin eluted from calcium sulfate appears effective against Staphylococcus, Clin 
Orthop Relat Res 466(6) (2008) 1383. 
[89] B. Mousset, M. Benoit, C. Delloye, R. Bouillet, J. Gillard, Biodegradable implants 
for potential use in bone infection, International orthopaedics 19(3) (1995) 157-161. 
[90] S.K. Nandi, P. Mukherjee, S. Roy, B. Kundu, D.K. De, D. Basu, Local antibiotic 
delivery systems for the treatment of osteomyelitis–A review, Materials Science and 
Engineering: C 29(8) (2009) 2478-2485. 
[91] J.M. Brady, D.E. Cutright, R.A. Miller, G.C. Battistone, E.E. Hunsuck, Resorption 
rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the 
abdominal wall of the rat, Journal of Biomedical Materials Research Part A 7(2) (1973) 
155-166. 
[92] T.J. Mäkinen, M. Veiranto, P. Lankinen, N. Moritz, J. Jalava, P. Törmälä, H.T. Aro, 
In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler, 
Journal of Antimicrobial Chemotherapy 56(6) (2005) 1063-1068. 
[93] P.B. Malafaya, G.A. Silva, R.L. Reis, Natural–origin polymers as carriers and 
scaffolds for biomolecules and cell delivery in tissue engineering applications, Advanced 
drug delivery reviews 59(4) (2007) 207-233. 
[94] B. Balakrishnan, A. Jayakrishnan, S.P. Kumar, M.A. Nandkumar, Anti-bacterial 
Properties of an In Situ Forming Hydrogel Based on Oxidized Alginate and Gelatin 
Loaded with Gentamycin, Trends in Biomaterials and Artificial Organs 26(3) (2012) 139-
145. 
[95] S.C. Chen, Y.C. Wu, F.L. Mi, Y.H. Lin, L.C. Yu, H.W. Sung, A novel pH-sensitive 
hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin 
for protein drug delivery, J Control Release 96(2) (2004) 285-300. 
[96] T.W. Chung, J. Yang, T. Akaike, K.Y. Cho, J.W. Nah, S.I. Kim, C.S. Cho, 
Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment, 
Biomaterials 23(14) (2002) 2827-2834. 
83 
 
[97] Y.-H. Lin, H.-F. Liang, C.-K. Chung, M.-C. Chen, H.-W. Sung, Physically 
crosslinked alginate/N, O-carboxymethyl chitosan hydrogels with calcium for oral 
delivery of protein drugs, Biomaterials 26(14) (2005) 2105-2113. 
[98] B. Sibaja, E. Culbertson, P. Marshall, R. Boy, R.M. Broughton, A.A. Solano, M. 
Esquivel, J. Parker, L. De La Fuente, M.L. Auad, Preparation of alginate-chitosan fibers 
with potential biomedical applications, Carbohydr Polym 134 (2015) 598-608. 
[99] S.W. Ueng, M.S. Lee, S.S. Lin, E.C. Chan, S.J. Liu, Development of a 
biodegradable alginate carrier system for antibiotics and bone cells, J Orthop Res 25(1) 
(2007) 62-72. 
[100] A.D. Augst, H.J. Kong, D.J. Mooney, Alginate hydrogels as biomaterials, 
Macromol Biosci 6(8) (2006) 623-633. 
[101] E.M. Pritchard, T. Valentin, B. Panilaitis, F. Omenetto, D.L. Kaplan, Antibiotic-
Releasing Silk Biomaterials for Infection Prevention and Treatment, Adv Funct Mater 
23(7) (2013) 854-861. 
[102] A.J. Choudhury, D. Gogoi, J. Chutia, R. Kandimalla, S. Kalita, J. Kotoky, Y.B. 
Chaudhari, M.R. Khan, K. Kalita, Controlled antibiotic-releasing Antheraea assama silk 
fibroin suture for infection prevention and fast wound healing, Surgery 159(2) (2016) 
539-47. 
[103] C. Correia, S. Bhumiratana, L.P. Yan, A.L. Oliveira, J.M. Gimble, D. Rockwood, 
D.L. Kaplan, R.A. Sousa, R.L. Reis, G. Vunjak-Novakovic, Development of silk-based 
scaffolds for tissue engineering of bone from human adipose-derived stem cells, Acta 
biomaterialia 8(7) (2012) 2483-92. 
[104] E.M. Pritchard, T. Valentin, B. Panilaitis, F. Omenetto, D.L. Kaplan, Antibiotic‐
Releasing Silk Biomaterials for Infection Prevention and Treatment, Adv Funct Mater 
23(7) (2013) 854-861. 
[105] J. Pachence, R. Berg, F. Silver, Collagen: its place in the medical device industry, 
Med. Device Diagn. Ind 9(1) (1987) 49-55. 
[106] K. Panduranga Rao, Recent developments of collagen-based materials for medical 
applications and drug delivery systems, Journal of Biomaterials Science, Polymer Edition 
7(7) (1996) 623-645. 
[107] A.C. McLaren, Alternative materials to acrylic bone cement for delivery of depot 




CHAPTER 4: Discussion 
Complex musculoskeletal wound infections, especially those complicated by biofilm-
forming bacteria, can lengthen the healing process, require additional surgeries, 
significantly increasing medical costs, and potentially result in patient morbidity [11, 12, 
130, 131].  The complex morphology of the wound potentiates the formation of biofilm, 
initiated by the adherence of invading planktonic bacteria; resulting in a bolstered 
resistance to antimicrobial agents [15, 16].  Consequently, biofilm-forming bacterial 
strains including Staphylococcus aureus and Pseudomonas aeruginosa are among the 
most common contaminants of complex musculoskeletal infections [17, 18].  Biofilm-
forming bacterial infections can be cleared with increased systemic antibiotic levels, as 
the minimal inhibitory concentration (MIC) of biofilm-forming bacterial colonies can be 
up to 1000 times higher than the planktonic form [14]; however, very high systemic 
antibiotic concentrations can cause adverse side effects such as nephrotoxicity and 
ototoxicity [19].  The clinical need for local drug delivery devices that effectively prevent 
bacterial contamination while demonstrating favorable biocompatibility, 
biodegradability, and the capability of antibiotic loading at the time of surgical 
intervention motivated research into antibiotic-loaded chitosan in many forms including 
films, coatings, hydrogels, and lyophilized sponges  [25, 27, 34, 121, 129].  Chitosan 
sponges were then modified into a paste form to address device migration and wound 
coverage, while maintaining the beneficial degradability, biocompatibility, and drug 
elution qualities [1, 36]. The research evaluated if chitosan/PEG blended sponges 
fabricated into an injectable form could function as a local antibiotic delivery device.  
The previously detailed studies sought to determine if lyophilized chitosan composited 
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with β-GP and processed into a paste can locally deliver antibiotics while 
demonstrating favorable biocompatibility, degradability, antibiotic elution, and 
material properties supporting the functional and clinical efficacy of the device.  
The goal of the work reported in the current study is to develop an infection-
prevention tool to be used in trauma care, effectively reducing the incidence of 
morbidity associated with musculoskeletal wounds resultant of traumatic injuries.  
Among other predictions, it was hypothesized the thermogel chitosan paste 
formulation would form a biocompatible, bio-resorbable, temperature-responsive 
drug delivery polymer exhibiting favorable injectability at room temperature (20ºC) 
and subsequent in situ gelation as the environmental temperature rises to bodily levels 
(37ºC).  Results from the cytocompatibility assessment of the thermogel exhibit 
viability responses by fibroblast-like cells not significantly different from the Control 
chitosan sponge samples, a positive finding.  However, based on cell count alone, the 
thermogel samples produced the lowest cell count among all experimental groups; 
indicating a potential area of improvement.  Additionally, the in vivo study of 
biocompatibility indicated the thermogel produced one of the highest inflammation 
reactions, second only to the PEG Paste samples.  It can be said the overall 
biocompatibility of the thermogel needs improvement.  In a study of the cytotoxic 
viability response of fibroblast cells to chitosan/β-GP hydrogel formulations by 
Ahmadi et al. [35], authors found lowering the content of β-GP in the formulation 
resulted in improved biocompatibility. Therefore, lowering the content of β-GP could 
potentially improve the biocompatibility of the thermogel experimental paste.  After 7 
days, the thermogel was enzymatically degraded to 40% ± 3% of the original mass.   
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The material properties of the thermogel paste were investigated via characterization 
of the degradation rate and the reactive force of ejection from both a small bore and large 
bore syringe.  The rate of degradation of the thermogel was similar to that of the PEG 
paste, a formulation that was shown to have favorable degradation characteristics for use 
in traumatic musculoskeletal injuries by Berretta et al. [33].  The thermo-responsive 
characteristic of the thermogel proved to be very beneficial.  The temperature dependent 
low viscosity polymer at room temper demonstrated very low injectability forces similar 
to the PEG Paste experimental group, proven to be highly injectable in a study by Beretta 
et al. [33], and significantly lower than a similar chitosan paste formulation in a report 
described by Rhodes et al. [1].   
The thermogel was also hypothesized to be capable of point-of-care antibiotic loading 
via hydration; and local, therapeutic release for at least 72 hrs.  The results of the the in 
vitro antibiotic release characteristics of the thermogel chitosan paste support this 
hypothesis; demonstrating an initial drug burst followed by a prolonged release of the 
dual-loaded antibiotics at therapeutic levels for a minimum of 72 hours in both the 
vancomucin and amikacin elution profiles.  Initially, both amikacin and vancomycin were 
released from the Control Sponge group at higher concentrations than all other 
experimental groups.  However, as the study progressed the thermogel demonstrated the 
most effecient release of amikacin while the PEG Paste proved the more effective carrier 
of vancomycin.  The antibiotic release profile of the thermogel paste is comparable to the 
favorable drug release characteristics studied in a report by Ruel-Gariepy et al. [63] of 
temperature-sensitive drug delivery systems consisting of chitosan hydrogels composited 
with β-GP.   
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While the subject size of the experiment is limited, cross-referencing applicable 
data such as the results of the in vivo antimicrobial study and the in vitro antibiotic 
elution study can help provide evidence about the antimicrobial efficacy of the 
thermogel.  Based on CFU counts alone, all methods of prophylaxis proved ineffective 
in preventing the bacterial adherence, colonization, and formation of biofilm.  The 
aggressive invasion, colonization, and biofilm formation of S. aureus is not surprising, 
as Staphylococcal bacterial species have been reported as the most commonly isolated 
microbial organisms from orthopaedic implants and devices [77], capable of efficient 
biofilm formation [78], with a rapid growth in bone tissue [79].  It has also has been 
noted that glycopeptide antibiotics, such as vancomycin, do not effectively penetrate 
tissue, an explanation for the poor antimicrobial efficacy in the femoral tissue samples 
surrounding the implant [80].  
Many observations can be made from the results of the P. aeruginosa CFU counts.  
For example, one could imply the P. aeruginosa organism does not thrive in the 
murine orthopaedic model as well as the S. aureus bacterial species did.  The 
thermogel appears to be the most effective antibiotic delivery system in preventing the 
colonization of P. aeruginosa as well as effectively eliminating the presence of the 
bacteria altogether.  A cross-reference of the results of the antibiotic elution profile, 
ZOI analysis, and the in vivo antimicrobial study supports the previous conclusion.  
Intermolecular interactions between the aminoglycoside antibiotic and the 
polyelectrolyte complex originating between the polycationic chitosan backbone and 
the β-GP additive could enhance the efficacy of drug delivery vehicle.  As amikacin is 
an aminoglycoside, electrostatic forces of attraction among the polyelectrolyte 
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complex of chitosan and β-GP and the positively charged amine groups of amikacin 
could be a reason for the favorable pharmacokinetics of the pairing; similar to the 
electrostatic forces which bind the antibiotic to the ribosomal structures of bacteria [64, 




CHAPTER 5: Conclusion and Future Recommendations  
The functional and clinical efficacy of the thermogel are evaluated within the 
scope of musculoskeletal wounds resultant of high energy trauma at risk of infection.  
Findings reveal thermogel is an injectable and degradable biomaterial capable of 
point-of-care antibiotic loading, and local, therapeutic antibiotic release.  While 
cytocompatibility is similar to other paste material controls, there was some 
inflammation observed in vivo.   The preclinical study of antimicrobial efficacy 
indicates thermogel as an effective infection prevention tool in an infected, complex 
musculoskeletal wound.   
The formulation of the thermogel should be further researched with hopes of 
modifications or additives capable of extending antibiotic elution time and efficacy, 
as well as improving the cytotoxic response and in vivo biocompatibility.  Potential 
modifications to the thermogel may be a lower β-GP content which could improve the 
cytocompatibility.  Additionally, a higher ratio of neutral chitosan particulate to 
acidic chitosan in the formulation could result in both improved compatibility and 
drug release characteristics.  Improvements could be made to the grinding process of 
the lyophilized chitosan sponges in order to achieve more uniform flake size which 
can be measured.  Also, a more finely ground particulate could help create a more 
homogenous paste.  If the in vivo compatibility of the paste can be improved, then 
future work will further evaluate the thermogel drug delivery system in an expanded 
preclinical model of complex, infected extremity trauma that more closely represents 
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I. Supplemental Studies 
Chitosan Paste Antibiotic Diffusion  
Objective  
An agar wound model was created to visually characterize the diffusivity of the 
antibiotics from the experimental chitosan drug delivery vehicles. 
Materials and Methods 
Agar molds were made using 20ml of 1.5% (wt) agar solution cast in petri dishes 
and chilled overnight at 3°C.  The goal was to create a reproducible pattern in the agar 
mold representative of a complex musculoskeletal wound.  A circle with a diameter of 
8mm was carved out of the center of the agar mold and 8 micro-channels radiating 
from the center, each 45° apart, were cut into the mold with a No. 11 scalpel blade 
(Fig 4A).  Experimental samples (n=3) of the PEG paste (26mg), thermogel paste 
(24mg), Control particulate (24mg), and Control sponges (24mg coupons) were 
hydrated with 0.2ml of PBS loaded with Rhodamine B (1mg/ml, Sigma-Aldrich, St. 
Louis, MO, USA), a fluorescent red dye with a similar molecular weight to amikacin, 
among other antibiotics.  The hydrated sponge or paste samples were placed in the 
center cavity of the agar mold, then gently shaken in an incubator (37°C) for 30 
minutes.  The diffusion pattern of Rhodamine B was fluoresced at an excitation 
wavelength of 553nm and emission of 627nm; imaged at 4X and stitched together into 
a montage via a Nikon inverted microscope Eclipse TE300 (Nikon Instruments 
Incorporation, Melville, NY, USA) operated by BIOQUANT OSTEO16 imaging 
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software (BIOQUANT, Nashville, TN, USA).  From the newly created montage, the area 
of fluorescence from the Rhodamine B was then calculated with the thresholding tool on 
the BIOQUANT OSTEO16 software which counted the number of pixels of a certain 
color and converted the pixel count to an area value in mm2 based on calibration with a 






Figure 3: Chitosan paste dry components prepared to be dyed with rhodamine B for the 
antibiotic diffusion test. 
 
 
Figure 4: (A) Agar mold with hydrated control sponge coupon in center cavity and 
radiating micro channels; (B) montage of fluoresced Rhodamine B diffusing from drug 





Results & Discussion 
The Control Sponge samples created an area of fluorescence by the model antibiotic 
solution which was significantly larger than all other experimental groups (p<0.02).  The 
calculated area of diffusion is supported by the in vitro antibiotic release profile.  Just as 
the Control Sponge samples displayed an initial burst release of the loaded antibiotics in 
the antibiotic elution study, the antibiotic diffusion maps helped to qualitatively model 
the quick release of antibiotics from the Control Sponge group.  The experimental design 
should be modified to examine the antibiotic diffusion characteristics over time to help 
better understand the mechanisms most essential to improving drug delivery 





Figure 5. Montage of rhodamine dyed antibiotic-PBS solution to model antibiotic 
diffusion from the experimental samples (n=3); (A) Control Sponge, (B) Control 





Figure 6: Calculated area of diffusion of rhodamine dyed antibiotic-PBS solution (n=3), 
data is presented as the average area of diffusion ± STD.  * represents a significantly 
lower diffusion area than the Control Sponge group (*p<0.019, **p<0.001) 
  




























Chitosan Paste Conformation in Agar Wound Model  
Objective 
The objective of the conformation study was to qualitatively assess and 
characterize the quality of thermogel paste conformation to model deep, narrow 
wound beds in comparison to other chitosan delivery system variations.  
Materials and Methods  
Model wound beds with narrow, deep crevices were made from 1.5% (wt) agar, 
cast in 50ml centrifuge tubes (Corning, Corning, NY, USA) with a crevice to the 
bottom, and chilled overnight at 3°C.  Experimental chitosan samples (n=3, 120mg of 
thermogel paste, control sponge and particulate, and 133mg of the PEG paste) are 
hydrated with 1ml of PBS loaded with Rhodamine B (1mg/ml, Sigma-Aldrich, St. 
Louis, MO, USA).  The model agar wound beds are then incubated to 37°C, the 
hydrated samples placed at the top of the wound (Fig. 7), and gently shaken in an 
incubator (37°C) for 30 minutes.  The model wound beds are then bisected and 
imaged.  The quality of conformation to the wound is then visually assessed, and 
qualitatively analyzed as a proof of principle (Fig. 8). 
Results & Discussion 
The level of conformation exhibited by samples from each experimental group can 
be visually assessed.  The Control Chitosan Sponge and Particulate displayed an 
inability to conform to the wound bed and deliver the loaded antibiotics to the far 
reaches of the model wound.  The Control Sponge displayed a burst release of the 
loaded solution as it was lodged in the top of the wound.  Both the thermogel and PEG 
106 
 
Paste experimental formulations displayed an improved coverage of the wound compared 
to the control chitosan groups.  Among the experimental paste groups, the thermogel 
appeared to more effectively distribute the antibiotic solution while conforming to the 
wound.  Findings from the current study are supported by the injectability results. A 
potential benefit of adding β-GP to the chitosan paste formulation is improved handling 
properties, due to the low viscosity of the paste at room temperature (20°C).  The authors 
of a review of thermo-responsive drug delivery systems noted the chitosan-acetic acid-β-
GP mixtures displayed a liquidlike behavior at low temperatures before undergoing a 













Figure 8: Model agar wound molds to evaluate paste conformity to narrow wound bed; 





Bio-adhesive Characterization of Chitosan Drug Delivery Devices 
Objective 
The bio-adhesive study was a preliminary assessment of the adhesive quality 
displayed by the chitosan paste and sponge to musculoskeletal tissue in a model 
porcine wound.  
Materials and Methods 
A longitudinal incision, approximately 7cm in length is made superficially to the 
scapular region of recently sacrificed neo-natal pigs gathered from the University of 
Memphis Animal Research Center.  Thermogel (600mg), PEG paste (667mg), control 
Sponges (600mg), and Control Particulate (600mg) samples were hydrated with 5ml 
of PBS.  All porcine test subjects were incubated to 37°C.  The chitosan samples (n=3) 
were then placed or injected into the wound.  The adhesive quality of the biomaterial 
was assessed as the implant migration distance within the wound after a 10ml syringe 
fitted with an 18-gauge needle (BD™, Franklin Lakes, New Jersey, USA) injected 
10ml of PBS subcutaneously at the head of the wound at a flow rate of 1ml/sec for 10 
seconds to model the natural exudate of a musculoskeletal wound.  As the PBS was 
injected into the wound, the subjects with the implanted biomaterial were fixed at a 
45° angle to the ground (Fig. 9).  
Results & Discussion 
No implant migration was observed among any experimental groups.  Therefore, 
all chitosan paste samples can be considered bio-adhesive for the desired application 
of therapeutic release of antibiotics in musculoskeletal wounds.  The mucoadhesive 
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properties of chitosan have been established, explained by the strong electrostatic force of 
the cationic amine groups lining the backbone of chitosan to the anionic mucins, 
glycosylated proteins highly concentrated on mucosal tissue surfaces such as pulmonary, 
corneal, intestinal, and gastric mucosal tissues [109].  Also, a portion of the 
mucoadhesive force can be attributed to the hydrogen bonding between the chitosan and 
the mucosal membranes [110].  Mucoadhesion contributes to chitosan adherence to a 
musculoskeletal wound via anionic molecules in the musculoskeletal tissue, such as the 







Figure 9: Experimental setup for adhesion testing; (A) model complex musculoskeletal 
wound, (B) PEG paste being injected into the wound, (C) subcutaneous saline injection at 





II.  Supplemental Figures  
Microscopic Analysis of NIH3T3 Cells  
 
Figure 10: Microscope images (40X) displaying cellular morphology of NIH3T3 cells 
after 72 hours of indirect exposure to: (A) Control Sponge, (B) Control Particulate, (C) 



















Figure 11A-E: Montage of histology slides made from excised rat limbs from functional 
compatibility study, stained with hematoxylin and eosin to emphasize the severity of the 
host foreign body response characterized by the aggregation of leukocytes and fibrous 
tissue formation, areas of interest are magnified to the right of the original image; (A) No 










Figure 12: Image results of zone of inhibition analysis of the eluate samples from the (A) 
Control Sponge; (B) Control Particulate; (C) PEG Paste; (D) Paste formulation from study 
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